Inflammation, infections and immunity by Alnwaisri, Heba F Mustafa
  
            
 
 
DOTTORATO DI RICERCA IN 
Scienze Cliniche 
Ciclo XXXII  
 
COORDINATORE Prof. Matucci Cerinic Marco 
 
 
 
 
 
INFLAMMATION, INFECTIONS AND IMMUNITY 
 
 
 
 
Settore Scientifico Disciplinare MED/09 
 
 
 
 
 
 
Dottorando                                                     Tutore 
Dott. Alnwaisri Heba F Mustafa            Prof. D’Elios Mario Milco 
 
 
 
Coordinatore 
Prof. Matucci Cerinic Marco 
 
 
Anni 2016/2019 
    
     Table of Contents 
 
Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients 
with active or latent tuberculosis 
Introduction…………………………………………………………………………..1 
Aim of the study……………………………………………………………………..21 
Materials and methods………………………………………………………………22 
Results……………………………………………………………………………….30 
Discussion……………………………………………………………………………34 
References…………………………………………………………………………...38 
Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 
Glycoprotein I in atherosclerosis inflammation of systemic lupus 
erythematosus patients with antiphospolipid syndrome 
Introduction………………………………………………………………………….45 
Aim of the study……………………………………………………………………..79  
Materials and  methods………………………………………………………………80 
Results……………………………………………………………………………….88 
Discussion…………………………………………………………………………..101 
References………………………………………………………………………….104 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
TUBERCULOSIS 
 
 
1  
Novel M. tuberculosis specific IL-2 ELISpot assay discriminates 
adult patients with active or latent tuberculosis 
 
 
INTRODUCTION 
 
 
Tuberculosis (TB) is a highly contagious infectious disease caused by Mycobacterium 
tuberculosis (Mtb); is one of the oldest recorded human diseases and is still a major health 
problem worldwide (Fig. 1), with 1.2 million deaths among HIV-negative people and an 
additional 251,000 deaths from TB among HIV-positive people estimated in 2018 [1]. 
Although nearly 9 million new cases of active TB are still reported annually, the majority 
of infected individuals do not develop this form of the disease: 1.7 billion people in the 
world’s population harbour a latent tuberculosis infection (LTBI). The LTBI is defined as a 
state of persistent immune response to Mtb in the absence of clinical, radiological and 
microbiological evidences [2]; people with LTBI are at risk of developing active TB 
disease during their lifetime [1]. 
The molecular epidemiological evidence suggests that the original infecting strain can lead 
to reactivation of TB up to 30 years after the initial infection [3]; this hypothesis is in 
keeping with previous reports that live and viable Mtb bacilli can be recovered from 
incidental TB lesions discovered post-mortem in individuals who died of other causes [4]. 
The preventive treatment of LTBI subjects is a key point to reduce TB at individual level, 
according to the WHO post 2015 End TB strategy. The early identification and treatment 
of patients with LTBI can reduce the burden of active TB, especially if the screening is 
performed on populations at high risk for progression to active disease, such as people with 
HIV infection or other immune deficiency, children aged under 5 years and household 
contacts with widespread exposure (all ages) to someone who has bacteriologically 
confirmed pulmonary TB [1, 5, 6]. 
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Figure 1.  Estimated TB Incidence rate 2018 (Adapted from WHO global tuberculosis report 
2019). 
 
 
 
Aetiology and pathophysiology 
 
The key concepts about microbiology and pathophysiology of TB became known slowly 
over the last 100 years. Mtb is an intracellular facultative bacillus first identified in 1882 by 
Robert Koch, who subsequently received the Nobel Prize in Physiology or Medicine for 
this discovery in 1905; the bacterium is also known as Koch's bacillus. Mtb and humans 
seem to have co-evolved during the period before the migration of humans out of Africa 
[7]. Mtb is a species of pathogenic bacteria in the family Mycobacteriaceae, Phylum 
Actinobacteria, order Actinomycetales.  Mtb is part of a complex (MtbC) whose species are 
characterised by 99.9% similarity at the nucleotide level and identical 16S rRNA 
sequences but differ widely in terms of their host tropisms, phenotypes, and pathogenicity. 
Assuming that they all are derived from a common ancestor, it is intriguing that some are 
exclusively human (M. tuberculosis, M. africanum, M. canettii) or rodent pathogens (M. 
microti), whereas others have a wide host spectrum (M. bovis) [8]. 
The bacillus requires oxygen to grow, it is highly aerobic and requires high levels of 
oxygen to duplicate, does not produce spores and is non-motile [9], his generation time is 
15-20 hours and this is extremely slow compared to other bacteria.  
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Mtb has an unusual, waxy coating on its cell surface primarily due to the presence of 
mycolic acid and is likely responsible for its resistance to desiccation and is a key virulence 
factor. The Mtb’s cell envelope differs substantially from the canonical cell wall structures 
of both gram-negative and gram-positive bacteria because in addition to the cell membrane 
and peptidoglycan layers, it contains mycolic acids and a vast array of lipids and 
glycolipids which confer extreme hydrophobicity to the outer surface of the organism. This 
coating makes the cells impervious to Gram staining and, as a result, Mtb can appear either 
Gram-negative or Gram-positive. Therefore, to identify Mtb with a microscope, Acid-fast 
stains such as Ziehl-Neelsen and the fluorescent stains such as auramine can be used [10]. 
Mtb cells are curved rod-shaped and are often seen wrapped together, due tothe presence of 
fatty acids in the cell wall that stick together; this appearance is referred to as cording, like 
strands of cord that make up a rope. Mtb can be grown in laboratory; commonly used 
media include liquids such as Middlebrook 7H9 or 7H12, egg-based solid media such as 
Lowenstein-Jensen, and solid agar-based such as Middlebrook 7H11 or 7H10 [9]. Visible 
colonies require several weeks to grow on agar plates. 
Humans are the only known reservoirs of Mtb. It can be spread through air droplets 
generated by cough or sneeze of person with Mtb lung infection (Pulmonary tuberculosis) 
and inhaled by uninfected person [11]. The respiratory droplet nuclei are small enough in 
size (1–2 mm or less) to pass into the lower respiratory tract escaping the anatomical 
barriers of nasopharynx and upper respiratory tract. The inhaled bacilli are deposited in 
alveolar space and ingested by alveolar macrophages (AMs). Although AMs are the 
primary innate cells that the bacilli encounter, other various phagocytic cells recruited to 
infected lung including neutrophils, monocyte-derived macrophages and dendritic cells 
(DCs) also take part in the phagocytic process [12]. Phagocytosis of Mtb by AMs and DCs 
initiates a cascade of events involving the production of cytokines and chemokines, which 
stimulate the activation of phagocyte anti-microbial activities and recruit blood 
polymorphonuclear leukocytes (PMN) and additional mononuclear leukocytes into the 
tissue to the site of infection. The accumulation of mononuclear leukocytes around foci of 
infected cells leads to the formation of a macrophage-rich cell mass known as the 
granuloma. Macrophages serve as the major host cell niche for the growth and survival of 
Mtb. However, these cells are also responsible for activation of the protective immune 
responses, both innate and acquired, which are necessary to control or eliminate the 
infection. That outcome of primary infection is most often a latently infected healthy 
human host, in whom the bacilli are held in check by the host immune response and persist 
4  
in a sub-clinical (quiescent) form, the bacteria may become dormant or may persist at low 
numbers. This phase of LTBI is manifested only with a positive tuberculin skin test (TST) 
or positive interferon gamma release assay (IGRA), such individuals can develop active 
TB later in life with impairment in the immune system. In contrast, in a minority of 
infected individuals, the host immune response fails to control the growth of bacilli, and 
progressive granulomatous disease develops Primary TB, facilitating spread of the bacilli 
via infectious aerosols coughed out into the environment and inhaled by new hosts [12]. 
In the earliest events in the lung, there is impact of the initial environment encountered by 
the bacterium, this environment depends on the cells it first encounters, and these, in turn, 
may depend the genetics of the host. 
Mtb is able to manipulate both the innate and acquired immune response of the host. Mtb 
expresses an extremely wide variety of virulence factors that counteract macrophage 
efforts in suppressing the pathogen. Among Mtb strategies we can include the inhibition of 
intracellular trafficking, the inhibition of autophagy, the acquisition of cytosol access, the 
induction of host cell death and the neutralization of toxic components as reactive oxygen 
species and toxic metals, Mtb lacks classical virulence factors such as toxins and its 
immune-escaping ability depends on the modulation of lipid metabolism, metal-transporter 
proteins, protease, proteins inhibiting the antimicrobial effectors of macrophages and many 
others [13]. In strong support of this concept, studies in zebrafish have demonstrated the 
ability of Mtb to manipulate the earliest recruitment of macrophages. This activity has been 
linked to the capacity of the bacterium to express lipids on its cell surface. Specifically, 
expression of the Mtb molecule phthiocerol dimycoceroserate (PDIM); limits innate 
recognition of Mtb, thereby reducing recruitment of Toll-like receptor (TLR)-activated 
macrophages; in addition to this subversion of the pathogen-recognition pathway, other 
lipids on the Mtb surface-the phenolic glycolipids (PGLs) - drive recruitment of permissive 
macrophages via a pathway that depends on the chemokine CCL2 and the chemokine 
receptor CCR2 [14]. 
Mtb infection can be influenced by autophagy, a process whereby components of the 
cytoplasm, including organelles and intracellular pathogens, are sequestered in an 
autophagosome and delivered to the lysosome for degradation. Activation of autophagy, 
by IFN-γ for example, results in phagosome maturation and an increase in its acidification 
and Mtb killing. However, in contrast to nonviable bacilli viable and virulent Mtb bacilli 
are able to prevent phagolysosomal fusion and persist in the phagosome, preventing 
acidification of the phagosomal compartment, thus adapting to the intracellular 
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environment of the macrophage and creating a niche for survival. Opsonisation of the 
bacilli prior to infection inhibits this blockade of phagolysosomal fusion. Macrophages can 
eliminate Mtb via different mechanisms if appropriately activated. Whilst IFN-γ is a key 
element in the containment of Mtb within macrophages, it is now widely recognized that 
performing this function requires the presence of vitamin D, because that has anti-
inflammatory and bacteriostatic effect [15]. 
Infection of macrophages with Mtb can induce necrotic death, defined by cell lysis, which 
allows exit from macrophages and therefore cell-to-cell spread of the bacilli. Alternatively, 
infection can result in apoptotic death of the macrophages that maintain an intact plasma 
membrane and is associated with diminished pathogen viability and enhanced immunity 
[12]. 
Macrophages and DCs are key cells in the immune response to Mtb by presenting antigens 
to T cells in the context of both major histocompatibility complex (MHC) class I and II. 
Host immune response against Mtb is mediated by cellular immunity, in which cytokines 
and Th1 cells play a critical role: Th1cells activate macrophages to kill the bacteria by 
secreting IFN-γ and TNF-α. Furthermore, macrophages and DCs play an important role in 
cells recruitment at the site of infection by secreting the proinflammatory cytokines IL-1 
and IL-6. DCs are prime antigen presenting cells (APCs) and they help in maximizing the 
recognition of antigens by T cells in the draining lymph nodes. 
The migration of Mtb away from the lung occurs despite the generation of granulomatous 
responses and it occurs 7-9 days after initial infection; as a consequence, there is a delay of 
up to 18-20 days before antigen-specific T cells accumulate to sufficient numbers in the 
lung to stop bacterial growth. Even after vaccination, when a population of circulating 
memory T cells is present, this accumulation of antigen-specific T cells is accelerated by 
only five days, and Mtb still have 15 days in which to define the lung lesion before T cells 
arrive [16]. 
The acquired immunity to Mtb requires contributions by multiple T cell subsets: CD4+, 
CD8+, γδ T cells and CD1-restricted T cells. The initiation of the acquired response is 
preceded by the appearance of bacteria in the draining lymph nodes. Inside the lymph 
nodes, T lymphocytes undergo a process of activation and expansion of the specific 
populations for the mycobacterial (Mtb) antigens. However, at this point, the largest part is 
done, and the infection is now established. The acquired response is delayed relative to the 
initiation of infection. Cellular immune response can be evidenced 2-6 weeks after Mtb 
infection by the development of a delayed-type hypersensitivity response (DTH) to 
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intradermal injected tuberculin or purified protein derivative (PPD). Multiple mechanisms 
may explain the delay in the onset of T cell activation and functional effector T cell 
responses after primary or secondary infection with Mtb. Such mechanisms include Mtb 
inhibition of apoptosis of macrophages and neutrophils, as discussed above, which delays 
or inhibits the antigen-presenting capacity of DCs; Foxp3+ regulatory CD4+ T cells, which 
not only inhibit but also delay the arrival of effector T cells in the lung during early TB; 
and IL-10, which inhibits and delays production of the cytokines IFN-γ and IL-17 by 
CD4+ T cells in the lung. Many of these mechanisms also operate via effects on DC 
migration and function [12]. Once the acquired response has been initiated, T cells must 
migrate from the circulation into the parenchyma of the lung and then into the infected site, 
which is composed largely of macrophages and dendritic cells expressing a variety of 
effector functions [17]; this predominantly mononuclear environment is thought to be 
maintained by the expression of the protective cytokine IFN-γ. 
CD4+ T cells play a dominant role in the protective response against Mtb. The Mtb reside 
within macrophage vacuoles; therefore, Mtb antigens are loaded on MHC class II and 
presented to CD4+ T cells through endocytic antigen presentation pathway. Upon 
activation, CD4+ T cells secret IFN-γ, IL-2 and TNF-α, which in turn activates 
macrophages. CD4+ cells are also important to enhancing the antigen presenting cell 
(APC) function through interaction of CD40-CD40L between CD4+ T cells and APC and 
this in turn can facilitate APC mediated induction of other T cells such as CD8+ T cells. 
The importance of IFN-γ production by CD4+ cells is particularly relevant at the early 
stages of Mtb infection as it is demonstrated that adequate IFN-γ levels can be obtained 
with 3 weeks of delay even in CD4+ - disrupted mice thanks to the compensation offered 
by other cell types like CD8+ [18]. Other roles played by CD4+ T cells include induction 
of apoptosis through perforin and granulysin, by Fas-Fas ligand interaction or TNF-α lytic 
pathways, help for B cells and CD8+ T cells, and production of other cytokines. CD8+ T 
lymphocytes have an activity against Mtb is conceivable considering that they recognize 
Mtb antigens through class I molecules of MHC, and produce IL-2, IFN-γ and TNF-α, 
which have a well-known role in controlling Mtb [19]. This direct cell-to-cell contact 
determines the apoptosis of the Mtb-infected cell especially macrophages depriving Mtb 
from its natural growth environment and at the same time reducing its viability by 
unknown mechanism [20]. On the other hand, CD8+ T cells produce IL-10 and TGF-β 
which favours the Mtb infection development. 
Following the development of adaptive immunity, a complex and well-coordinated 
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mechanism is established between both immunity mechanisms, innate and adaptive, which 
seal the Mtb inside granulomas that isolate the bacteria from the rest of body [21]. This 
mechanism develops in at least 90% of the infected subjects and leads to LTBI. During 
LTBI, Mtb ceases to divide but doesn’t die; thereby preventing eradication of the pathogen 
from the infected body, the subject is generally positive for the TST and for the IGRA. 
The mechanisms inducing and maintaining the persistence of a pathogen in LTBI are still 
unclear.Wayne and Sohaskey refer to the latent physiological state as “non-replicating 
persistence” (NRP) when the bacilli evade the host immune response and survive inside the 
hostile macrophage environment, in a two step adaptation conditions: first in a stage of 
microaerophilic (NRP-1) and then anaerobic (NRP-2) persistence [22]. Since 1996, the 
Wayne model has been used in hundreds of studies, which greatly increased our knowledge 
about the Mtb dormancy. For example, Rustad et al. described expression of the 230 Mtb 
genes referred to as EHR (Enduring Hypoxic Response) genes: a rise of gene expression 
followed the induced DosR-mediated hypoxic response on days 4-7 of hypoxia. These 
genes include a surprising number of transcriptional regulators that could control the 
program of bacteriostasis [23].  
The Mtb two-component system DosR-DosS (also called DevR-DevS) has received 
significant attention over the last decade as a key regulatory mechanism underlying Mtb 
dormancy. The histidine kinases DosS (DevS) and DosT phosphorylate and activate the 
cognate response regulator DosR in Mtb. Originally found to be induced by exposure of 
Mtb to progressive hypoxia, the dormancy survival regulator (DosR) regulon comprises 48 
genes, including several believed to play an important role in Mtb adaptation to hypoxic 
stress, as well as energy acquisition from alternative carbon sources, such as fatty acid 
metabolism, and nitrate reductase genes. The DosR regulon acts shifting metabolism away 
from aerobic respiration and maintaining energy levels and redox balance [24]. 
The development of Mtb dormancy is a complex process, which radically remodels the 
genetic, metabolic, and functional systems of the mycobacterial cell; expression of certain 
genes changes the metabolism of bacterial cells. A number of studies have demonstrated 
that the transformation into dormant (nonreplicating) forms involves major cellular 
metabolic pathways. In general, characteristic of the metabolic shift is slowdown of all 
principal cellular processes, which results in the arrest of cell growth and division. Changes 
in the protein synthesis as a direct consequence of the changes in the transcriptome 
determine the further cell functioning. The whole proteome profiling studies have shown a 
downregulated expression of over 1500 proteins during Mtb dormancy. In addition, a 
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dormant Mtb synthesizes the proteins (including enzymes) that are not typically expressed 
during active replication [25]. As is known, the energy metabolism is changed towards a 
decline in the intracellular ATP level and an increase in the NADH/NAD ratio [24, 26]. 
Among  the enzymes expressed during this dormancy is L-alanine dehydrogenase (Ala-
DH), which converts pyruvate to alanine and glyoxylate to glycine concurrent with the 
oxidation of NADH to NAD; it is involved in the metabolic remodeling of Mtb through its 
possible interactions with both the glyoxylate and methylcitrate cycle. 
The ald gene encodes Ala-DH, NAD (H)-dependent L-alanine dehydrogenase (EC 1.1.4.1; 
Ald) was identified as one of the major antigens present in culture filtrates of Mtb. The 
overexpression of the ald gene (Rv2780) is found under hypoxia and nutrient-starvation 
conditions. Upregulation of ald expression by alanine or under respiration-inhibitory 
conditions is mediated by AldR, a member of the Lrp/AsnC family of transcriptional 
regulators. Increased levels of this enzyme have been linked to the generation of alanine 
for peptidoglycan biosynthesis and maintain of cellular NADH/NAD+ homeostasis. The 
catabolic role of was showed to be required for mycobacterial utilization of alanine as sole 
nitrogen source and the adaptation of Mtb in anaerobic dormant stage in LTBI [27]. 
Ala-DH has important role in other bacteria that have specialized persistence programs, 
such as sporulation. In Myxococcus xanthus, an ald mutant showed delayed aggregation 
and reduced levels of sporulation. Ala-DH of Mtb is a unique enzyme involved in 
peptidoglycan biosynthesis since it only accepts L-alanine as substrate in contrast to Ala-
DH from all other organisms studied, which also use serine as a substrate [28, 29]. In 
mycobacteria, it was identified as an enzyme absent from the vaccine strains of M. bovis 
BCG but present in virulent Mtb [30]. The ald gene of M. bovis contains a single 
nucleotide deletion and therefore lacks this enzyme. It was suggested that impairment of 
M. bovis BCG replication in humans due to the lack of a functional Ala-DH inhibited the 
development of protective immunity [31]. Ala-DH is present in other pathogenic 
mycobacteria such as M. marinum and M. ulcerans. 
Griffin proposed that the main role of Ala-DH during hypoxia is to maintain the redox 
balance of Mtb. NAD is the principal oxidant in the cell and essential for many reactions, 
so NADH must be rapidly oxidised to prevent inhibition of important processes. The ratio 
between NAD and NADH is tightly regulated by redundant systems, and in Mtb is 
generally between 1:3 and 1:10. When oxygen levels decrease or aerobic respiration is 
blocked by NO the ratio of NAD to NADH shifts. This shift is also seen in Mtb in the lungs 
of mice, indicating that redox stress is present in vivo. In response to decreasing oxygen, 
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Mtb induces a set of dormancy genes that enable this obligate aerobe bacterium to adapt to 
and survive in low oxygen conditions. The ald transcription is upregulated in Mtb late in 
NRP-2 stage and then decreases as the cells enter the general shutdown characteristic of 
dormancy. Although transcription of ald decreases, the protein is stably maintained so that 
the cell will be ready to reactivate when oxygen levels increase. The late expression of ald, 
and a defect in regrowth of an ald mutant of Mtb suggested a role for Ala-DH during 
reaeration, infact, it is proposed that Ala-DH is involved in maintaining the optimal 
NADH/NAD ratio not only during dormancy, but also during reactivation when oxygen 
levels increase enough to support regrowth of Mtb [32]. Ala-DH catalyses the NADH-
dependent conversion of pyruvate and ammonia to L-alanine and is involved in microbial 
carbon and nitrogen metabolism. The mycobacterial enzyme is secreted into the culture 
medium and is identical with the 40-kDa antigen that has been identified in culture filtrates 
of Mtb [33]. In solution, the enzyme forms a hexamer of six identical subunits (predicted 
molecular mass = 38,988 Da per subunit), as observed for most Ala-DH from other 
species. Agren et al. [27] demonstrated that three-dimensional structures of Ala-DH could 
alter the expression profile for adaptation to a state of latent infection. The authors also 
showed that the conformation and crystal structure of Ala-DH was changed from open to 
closed ternary forms in the phase of latent infection, which indicated the different host 
immune responses of LTBI. The structures reveal a conformational transition in the form 
of a 16° rotation upon binding of the dinucleotide, from an “open” to a “closed” 
conformation (Fig. 2). This conformational change ensures proper orientation of the 
substrates for hydride transfer to occur and excludes bulk water from the active site. The 
crystal structures and complementary site-directed mutagenesis studies support a 
mechanistic model where conformational changes are required to allow access of water 
and ammonia to the active site and where the active-site residues His96 and Asp270 
participate in proton transfer steps during catalysis. The experimental studies have 
demonstrated that upon the binding of the coenzyme, Ala-DH undergoes a large-scale 
conformational transition from the open-apo to the closed-holo states, in which the 
substrate-binding domain (SBD) rotates by 16 toward the NAD-binding domain (NBD) 
[27]. The NBD includes a central seven-stranded β-sheet, as well as several surrounding α-
helices; the SBD consists of an eight-stranded β-sheet and several α- helices. The crystal 
structure of the open-apo and closed-holo states of the protein have been determined by X-
ray crystallography, which can be downloaded from the Protein Data Bank (PDB) with the 
access codes 2VOE and 2VHZ, respectively [34, 27]. 
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Tuberculosis diagnosis and guidelines 
 
The TB disease is a leading cause of infectious disease morbidity and mortality worldwide, 
with many diagnostic uncertainties, and control relies on the identification and preventive 
treatment of individuals who are latently infected with Mtb, is important strategy in TB 
elimination. However, direct identification of LTBI is currently unavailable. Reactivation 
TB can be averted by preventive treatment. Currently available treatments have an efficacy 
ranging from 60% to 90% [35]. The potential benefit of treatment needs to be carefully 
balanced against the risk of drug-related adverse events. The presence of TB disease must 
be excluded before treatment for LTBI is initiated because failure to do so may result in 
inadequate treatment and development of drug resistance [36].  
Targeted testing is an essential TB prevention and control strategy that is used to identify, 
evaluate, and treat persons who are at high risk for LTBI or at high risk for developing TB 
 Figure 2. Molecular architecture of mycobacterial Alanine Dehydrogenase. Two forms of 
structures for Ala-DH including the dimer (Figure 2C) and the hexamer (Figure 2D) states. The 
hexameric molecule is made of three-fold non-crystallographic axes, and two monomers nearby 
form the fold axis. As shown in Figure 2A, each monomer of Ala-DH is composed of a 
substrate-binding domain (residues 1-128 and 309-371) and a NAD-binding domain (residues 
129-308), which are connected by two α- helixes. 
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disease once infected with Mtb. 
The LTBI diagnosis is based on information gathered from the medical history, TST or 
Interferon-gamma release assays (IGRAs) result, chest radiograph (CXR), physical 
examination, and in certain circumstances, sputum examinations. 
The lack of a gold standard for LTBI diagnosis has created uncertainty about test 
performance. The TST and IGRAs are current indirect methods for TB screening; neither 
IGRAs nor TST can distinguish active TB from LTBI [37, 38]. 
WHO recommends that either a TST or IGRA must be used to test for LTBI in both high- 
and low-TB-burden countries and that active TB disease be ruled out prior to prescribing 
preventive treatment, as per WHO guidelines [39]. There is no strong evidence that one 
LTBI test should be preferred over the other. The choice will depend on the availability, 
cost and the health infrastructure. The evidence reviewed and the recommendations in the 
2018 consolidated guidelines on LTBI apply to the use of the TST and commercially 
available IGRAs (QuantiFERON®-TB Gold Plus and T-SPOT®.TB) [39, Fig.  3]. 
Active TB patients, in addition to TST positivity and a generally positive QFT-G-IT that 
can be negative in a certain number of cases, were detected through clinical, 
microbiological and radiological findings. 
The diagnosis' confirmation required Mtb identification through fluorescence microscopy, 
polymerase chain reaction (PCR) as WHO-approved molecular test such as TB Xpert® 
MTB/RIF assay [39] or cultural assays upon 3 biological samples, such as sputum or 
bronchoalveolar lavage (BAL) for respiratory diseases, tissue biopsies, drainage liquid or 
needle aspirates for extrapulmonary localizations [40]. 
CXR, is an important tool for triaging and screening for pulmonary TB, and it is also 
useful to aid diagnosis when pulmonary TB cannot be confirmed bacteriologically. CXR 
can be used to select individuals for referral for bacteriological confirmation, and the role 
of radiology remains important when bacteriological tests cannot provide a clear answer. 
The lack of a gold standard for LTBI diagnosis has created uncertainty about test 
performance. Whilst TST remains the most widely used, test performance is suboptimal in 
populations with a high prevalence of BCG vaccination and infection with environmental 
mycobacteria. There are two important causes of false-positive results: nontuberculous 
mycobacterium (NTM) infection and prior BCG vaccination, NTMs are not a clinically 
important cause of false-positive TST results, except in populations with a high prevalence 
of NTM sensitization and a very low prevalence of TB infection. 
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. 
The impact of BCG on TST specificity depends on when BCG is given and on how many 
doses are administered. If BCG is administered at birth (or during infancy) and not 
repeated, then its impact on TST specificity is minimal and can be ignored while 
interpreting the results. In contrast, if BCG is given after infancy (e.g., school entry) and/or 
given multiple times (i.e., booster shots), then TST specificity is compromised [41]. 
 The TST is one of the few tests that have been continuously in use for about 100 years in 
clinical medicine. It attempts to measure a memory of cell-mediated immunity in the form 
of a DTH response to the most commonly used PPD of tuberculin. The TST, performed 
using the Mantoux technique [42], consists of the intradermal injection in 0.1ml of 5 
tuberculin units (TU) of PPD-S or 2 TU PPD RT23 (these are considered equivalent); TST 
reactions in adults are measured by the diameter of induration, measured 48-72 h after 
antigen injection. Clinically, the TST reaction may already start a few hours after the 
injection of tuberculin PPD with a white or rose-coloured induration of the skin as a type-I 
or type-III immune reaction followed by the DTH reaction, which peaks after 48-72 h and 
may last for up to 1 month, depending on the quality and quantity of the initial reaction. 
Strong reactions may result in tissue necrosis. A positive TST reaction may lead to 
persistent discoloration of the skin. In interpreting a positive TST, it is important to 
consider much more than only the size of the induration (Fig. 4). Rather, the TST should 
be considered according to three dimensions: size of induration (for the current test as well 
as in relation to the induration on a previous test, if done), pretest probability of infection, 
and risk of disease if the person were truly infected. Menzies and colleagues developed a 
Figure 3. Diagnostic tests as TST or IGRA for active TB and LTBI. WHO Standard for 
diagnosing LTBI; recommended either TST or IGRA can be used to test for LTBI. 
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simple, Web-based, interactive algorithm - the Online TST/IGRA Interpreter (version 3.0; 
www.tstin3d.com) - that incorporates all these dimensions [43] and also computes the risk 
of serious adverse events due to treatment.  
 
 
Based on the sensitivity and specificity of the PPD TST and the prevalence of TB in 
different groups three cut-points have been recommended for defining a positive tuberculin 
reaction: > 5 mm, > 10 mm, and > 15 mm of induration. For persons who are at highest 
risk for developing active TB if they are infected with Mtb (i.e., persons with HIV 
infection, who are receiving immunosuppressive therapy, who have had recent close 
contact with persons with infectious TB nor who have abnormal CXR consistent with prior 
TB), > 5 mm of induration is considered positive. For other persons with an increased 
probability of recent infection or with other clinical conditions that increase the risk for 
progression to active TB, > 10 mm of induration is considered positive. These include 
recent immigrants (i.e., within the last 5 yr) from high prevalence countries; injection drug 
users; residents and employees of high-risk congregate settings (including health care 
workers with exposure to TB); mycobacteriology laboratory personnel; persons with 
clinical conditions such as silicosis, diabetes mellitus, chronic renal failure, leukemias and 
lymphomas, carcinoma of the head or neck and lung, weight loss of > 10% ideal body 
weight, gastrectomy, and jejunoileal bypass;  and children younger than 4 year of age or 
infants, children, and adolescents exposed to adults in high- risk categories. For persons at 
low risk for TB, for whom tuberculin testing is not generally indicated > 15 mm of 
induration is considered positive [44]. 
IGRAs are in vitro blood tests of cell-mediated immune response; they measure T-cell 
 Figure 4. Tuberculin skin test (TST), performed using the Mantoux technique. 
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release of IFN-gamma following stimulation by antigens specific to the MtbC, with the 
exception of BCG substrains. IGRAs measure interferon gamma release by memory T-
cells after stimulation with Mtb-specific antigens absent in BCG and most NTMs and are, 
therefore, considered to be specific [42]. 
In 2001, QuantiFERON (QFT) became the first IGRA approved by the Food and Drug 
Administration (FDA) as an aid for diagnosing Mtb infection. This test used an enzyme-
linked immunosorbent assay (ELISA) to measure the amount of IFN-γ released in response 
to PPD compared with controls, QFT specificity was less than that of TST despite the use 
of M. avium antigen as a control for nontuberculous mycobacterial sensitization and saline 
as a negative control [45]. QFT has not been available commercially since 2005. To 
improve specificity, new IGRAs were developed. These IGRAs assess response to 
synthetic overlapping peptides that represent specific Mtb proteins, such as early secretory 
antigenic target-6 (ESAT-6) and culture filtrate protein 10 (CFP-10). These proteins are 
present in all Mtb and they stimulate measurable release of IFN-γ in most infected persons, 
but they are absent from BCG vaccine strains and from most NTM. Thus, as test antigens, 
these proteins offer improved test specificity compared with PPD. However, ESAT-6 and 
CFP-10 are present in M. kansasii, M. szulgai, and M. marinum, and sensitization to these 
organisms might contribute to the release of IFN-γ in response to these antigens and cause 
false-positive IGRA results. Because ESAT-6 and CFP-10 are recognized by fewer T 
lymphocytes and stimulate less IFN-γ release compared with PPD, a more sensitive ELISA 
than was used for QFT is required to measure IFN-γ concentrations and responses to ESAT 
6 and CFP-10 [45]. 
In 2005, the QuantiFERON-TB Gold test (QFT-G) (Cellestis Limited, Carnegie, Victoria, 
Australia) became the second IGRA approved by FDA as an aid for diagnosing Mtb 
infection. It assesses the immunologic responsiveness of tested patients to ESAT-6 and 
CFP-10. In the QFT-G test, separate aliquots of fresh whole blood are incubated with 
controls and with two separate mixtures of peptides, one representing ESAT-6 and the 
other representing CFP-10. The amount of IFN-γ released in response to ESAT-6 or CFP-
10 (i.e., the ESAT-6 response or the CFP-10 response) is calculated as the difference in 
IFN-γ concentration in plasma from blood stimulated with antigen minus the IFN-γ 
concentration in plasma from blood incubated with saline (i.e., Nil). For QFT-G, the TB 
Response is the higher of the ESAT-6 Response or the CFP-10 response. A stipulation for 
FDA approval was inclusion of interpretation criteria that addressed the potential for false-
positive results accompanying high Nil values (i.e., >0.7 IU/ml) [45]. 
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In October 2007, the Quantiferon Gold In Tube (QFT-G-IT) became the third IGRA 
approved by FDA. Their tubes contain test antigens that consist of a single mixture of 14 
peptides representing the entire amino acid sequences of ESAT-6 and CFP-10 and part of 
the sequence of TB7.7 (Rv2654c), which is not an RD1 antigen. The two accompanying 
tubes serve as negative and positive controls: the negative-control tube contains heparin 
alone, and the positive-control tube contains heparin, dextrose, and phytohemaglutinin. 
Blood (1 ml) is collected into each of the three tubes, mixed with the reagents already in the 
tubes, and incubated for 16-24 hours. Plasma is separated, and the IFN-γ concentration in 
the plasma is determined using the same sensitive ELISA used for QFT-GT (Fig. 5). 
To interpret QFT-G-IT as approved by the FDA, the TB response is calculated as the 
difference in IFN-γ concentration in plasma from blood stimulated with antigen (i.e., the 
single cocktail of peptides representing ESAT-6, CFP-10, and TB7.7) minus the IFN-γ 
concentration in plasma from blood incubated without antigen (i.e., Nil). The result is 
reported as quantification of IFN-γ in international units (IU) per millilitre [45]. 
As a particular advantage of in vitro testing, stimulation reactions with negative control 
and positive control (mitogen stimulus) are carried out in parallel to primarily evaluate test 
performance with respect to background signals or general T-cell responsiveness. 
 
Figure 5. Overview of the stages of the QuantiFERON-TB GOLd® IN Tube assay. 
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 In the setting of immunodeficiency, an impaired mitogen response may, in addition, be 
interpreted as a meaningful measure for the assessment of the overall extent of 
immunosuppression. Therefore, unlike skin testing, in vitro tests may be able to 
discriminate true negative responses from anergy. 
T-SPOT.TB test (Oxford Immunotec, Oxford, UK) is a type of enzyme-linked immunospot 
assay (ELISpot), used for TB diagnosis, which belongs to the group of IGRAs, the test was 
approved by FDA on July 2008 [46, Fig. 6]. T-SPOT.TB test enumerates the response of 
effector T cells that have been sensitized to Mtb antigens. For this test peripheral blood 
mononuclear cells (PBMCs) are incubated with control materials and two mixtures of  
peptides, one representing the entire amino acid sequence of ESAT-6 and the other 
representing the entire amino acid sequence of CFP-10. The test uses an ELISpot to detect 
increases in the number of cells that secrete IFN-γ (represented as spots in each test well) 
after stimulation with antigen as compared to the media control (Nil). The result is reported 
as the number of IFN-γ -producing T cells (spot-forming cells, SFC). An individual is 
considered positive for Mtb infection if the spot counts in the TB antigen wells exceed a 
specific threshold relative to the negative-control wells [42].  
The T-SPOT interpretation criteria approved by FDA for use in the USA differ from those 
used in other countries. Also, the majority of published studies evaluating T-Spot have 
used criteria that differ from those approved by FDA. The interpretation criteria for T-
SPOT.TB approved by FDA included a borderline interpretation for a TB response equal 
to five, six, or seven [46]. 
 
 
Figure 6. T-SPOT.TB: an in vitro diagnostic test for detection of T cells specifically 
activated by Mtb antigens. 
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The last IGRA version, QuantiFERON-TB Gold Plus (QFT-P) (QIAGEN, Germantown, 
MD, USA), is 4th Generation QuantiFERON was approved by the USA. FDA on June 8, 
2017. QFT-P employs two antigen tubes (TB1 and TB2) for diagnosis Mtb infection. 
Major differences between the QFT-G-IT and the QFT-P include the removal of TB7.7 
peptides, the addition of a second antigen tube containing shorter peptides for ESAT-6 and 
CFP-10, aimed to elicit a response from CD8+ T-cells (Fig. 7). Currently, there is little 
data comparing the results of QFT-P and the QFT-G-IT based on blood collection. QFT-P 
is expected to be more sensitive than QFT-G-IT; however, early publications on the 
sensitivity of QFT-P has shown equal sensitivity compared to QFT-G-IT. Studies 
conducted in Japan, Italy, Germany, Belgium, and the Netherlands (low TB prevalence 
countries) found  no significant differences between the sensitivity among  
bacteriologically and  non- bacteriologically confirmed active TB patients and specificity 
among  healthy subjects with  low or no risk for TB between the third generation (QFT-G-
IT) and fourth generation (QFT-P) assays. A study conducted among U.S. Health Care 
Workers (HCWs) found a positivity rate of 4% in the study population when using QFT-G-
IT and 6% when using QFT-P with 96% agreement between the assays [47]. 
 
 
 
Treatment of Tuberculosis 
 
Effective management requires prompt recognition using a combination of clinical, 
radiographic, microbiological, and histopathologic hallmarks and initiation of appropriate 
multidrug therapy. Effective medical therapy for TB has existed for more than half a 
century, yet TB remains among the most pressing public health issues of our day 
throughout the world but disproportionately afflicts low income nations. The challenges to 
effective solutions include lack of access to diagnosis and treatment, the frequent 
Figure 7. QuantiFERON-TB Gold Plus (QFT-P). 
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coexistence of epidemics of TB and HIV, and the increasing prevalence of multidrug-
resistant tuberculosis (MDR-TB). 
Patients with active TB should be treated with multiple agents to achieve bacterial 
clearance, to reduce the risk of transmission, and to prevent the emergence of drug 
resistance. Antituberculosis (anti-TB) medicines or drugs are classified as first- and 
second- line drugs. First-line anti-TB drugs used to treat drug-susceptible TB (DST), 
include Isoniazid (INH), rifampicin (RIF), ethambutol (EMB), pyrazinamide (PZA) and 
streptomycin (SM), (streptomycin is now considered a second-line TB medicine and used 
only as a substitute for amikacin when amikacin is not available or there is confirmed 
resistance to it). Second-line anti-TB medicine or drug is an agent reserved for the 
treatment of drug-resistant TB (DR-TB) include the Fluoroquinolones ((Ofloxacin (OFX), 
levofloxacin (LEV), moxifloxacin (MOX) and ciprofloxacin (CIP)), Injectable anti-TB 
drugs are the aminoglycosides (Kanamycin (KAN), amikacin (AMK) and capreomycin 
(CAP)). Less- effective second-line anti-TB drugs- Ethionamide (ETH)/Prothionamide 
(PTH), Cycloserine (CS)/Terizidone, P-aminosalicylic acid (PAS) [48]. 
For initial empiric treatment of TB, initial phase for 8 weeks, patient starts on a 4-drug 
regimen: isoniazid, rifampicin, pyrazinamide and either ethambutol or streptomycin. Once 
the TB isolate is known to be fully susceptible ethambutol or streptomycin, if it is used as 
fourth drug, can be discontinued. The first-line anti-TB agents are bactericidal and 
particularly effective against metabolically active organisms. Continuation phase for 16 
weeks on 2 drugs, rifampicin and isoniazid. Effectively treating simplest forms of TB take 
between 6-9 months [48]. During drug treatment of human TB, susceptible organisms can 
be eradicated from sputum rapidly, usually within 2 months, but a continuation phase for 
months of treatment after cultures are negative is required to prevent re-emergence of the 
disease. Organisms that are still viable after months of treatment to which they are 
susceptible are termed persistors. Currently available TB drugs target mechanisms of cell 
growth and metabolism. Persistent organisms are metabolically less active, or differently 
active, making attacks on growth and metabolism less effective. It is unclear what signals 
initiate and maintain this less metabolically active state, but hypoxia and starvation within 
granulomas or phagocytic cells have been proposed. Rifampicin is somewhat active against 
persistors. This property may be what makes it critical to short course therapy. For a drug to 
kill persistors it will need to target some aspect of cell metabolism that remains vital in the 
less metabolically active state. Mtb organisms develop spontaneous resistance mutations 
that can interfere with a drug’s mechanism of action, activation or entry into the cell. 
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Resistance emerges as a consequence of selective pressure caused by monotherapy. 
Treatment with multiple drugs to which the organism is susceptible will prevent this 
selection rates of drug resistance rise in the community, the potential for inadvertent 
monotherapy and subsequent emergence of more advanced drug resistance increases. 
 The patients with primary MDR-TB tend to exhibit a greater extent of lung cavitation and 
lower number of calcified nodules compared to patients with DST. A review also shed light 
on thicker cavity walls in MDR-TB lung lesions further to extensive tissue loss, the intense 
inflammatory processes unleashed by MDR-Mtb infection in the lungs [49]. Interestingly, 
patients with MDR-TB have also been shown to have slightly higher T-cell counts and IgM 
titres in serum compared to patients with DST [50].  
TB strains with drug resistant (DR-TB) are more difficult to treat than DST, and threaten 
global progress towards the targets set by the End TB Strategy of the WHO. Globally in 
2018, 51% of bacteriologically confirmed pulmonary TB cases were tested for rifampicin 
resistance, up from 41% in 2017 [1, 5]. The latest treatment outcome data show success 
rates of 85% for TB, 75% for HIV-associated TB, 56% for MDR/ Rifampicin resistance 
(RR-TB) and 39% for extensively drug-resistant (XDR-TB) [1]. MDR/RR-TB is harder to 
treat. In 2018, WHO released a Rapid Communication. Recommending the use of 
levofloxacin (or moxifloxacin), bedaquiline, linezolid, clofazimine and cycloserine (or 
terizidone) in longer MDR-TB regimens [39]. Second- line TB-drugs, three medicines are 
used for the treatment of DR-TB include levofloxacin or Moxifloxacin, Bedaquiline and 
linezolid are strongly recommended to use in a longer regimen, which is completed with 
other medicines ranked by a relative balance of benefits to harms. The proposed total 
duration of longer MDR-TB regimen is about 18-20 months, modified depending upon 
patient response. The standardised, short MDR-TB regimen maybe offered to eligible 
patients who agree to a briefer treatment (9-12 months). Injectable agents are no longer 
among the priority medicine when designing long MDR-TB regimens, with Kanamycin 
and capreomycin not recommended any more, and fully oral regimens should thus become 
the preferred option for most patients [39,48]. 
XDR-TB, is a form of TB which is resistant to at least four of the core anti-TB drugs. 
XDR-TB involves resistance to the two most powerful anti-TB drugs, isoniazid and 
rifampicin, also known as MDR-TB, in addition to resistance to any of the 
fluoroquinolones and to at least one of the three injectable second-line drugs. MDR/RR-TB 
and XDR-TB both take substantially longer to treat than ordinary, and require the use of 
second-line anti-TB drugs, which are more expensive and have more side-effects than the 
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first-line drugs used for drug-susceptible TB [39]. Treatment of XDR-TB or treatment-
intolerant /non-responsive MDR-TB has historically been lengthy and complex; most 
XDR-TB patients currently take a combination of as many as eight antibiotics, some 
involving daily injections, for 18 months or longer [5]. In 2019, FDA approves the BPal 
regimen for treatment of  highly  drug resistance forms of tuberculosis [51], three-drug 
regimen consisting of bedaquiline, pretomanid and linezolid-collectively referred to as the 
BPal regimen-was studied in the pivotal Nix-TB trial across three sites in South Africa. 
Even if all active cases of TB could be eliminated, the large pool of latently infected 
individuals would serve as a significant, reservoir for development of active cases for 
decades [35]. Preventive treatment which is offered to individuals who are considered to be 
at risk for TB disease in order to reduce that risk. Also referred to as LTBI treatment or 
preventive therapy. WHO guidelines for the management of LTBI are currently only 
available for people living with HIV and for children below 5 years of age who are 
household contacts of TB cases [39]. Isoniazid monotherapy for 6 months is recommended 
for treatment of LTBI in both adults and children in countries with high and low TB 
incidence, (strong recommendation, high-quality evidence. Existing recommendation) 
Rifampicin plus isoniazid daily for 3 months should be offered as an alternative to 6 
months of isoniazid monotherapy as preventive treatment for children and adolescents aged 
< 15 years in countries with a high TB incidence, (strong recommendation, low-quality 
evidence. New recommendation). Rifapentine (RPT and isoniazid weekly for 3 months 
may be offered as an alternative to 6 months of isoniazid  monotherapy as preventive 
treatment for both adults and children in countries with a high TB incidence. (Conditional 
recommendation, moderate-quality evidence. New recommendation). The following 
options are recommended for treatment of LTBI in countries with a low TB incidence as 
alternatives to 6 months of isoniazid monotherapy: 9 months of isoniazid, or a 3-month 
regimen of weekly rifapentine plus isoniazid, or 3-4 months of isoniazid plus rifampicin, or 
3-4 months of rifampicin alone. (Strong recommendation, moderate–high-quality evidence. 
Existing recommendation). In settings with high TB incidence and transmission, adults and 
adolescents living with HIV who have an unknown or a positive TST and are unlikely to 
have active TB disease should receive at least 36 months of isoniazid preventive treatment 
(IPT), regardless of whether they are receiving  antiretroviral therapy (ART). IPT should 
also be given irrespective of the degree of immunosuppression, history of previous TB 
treatment and pregnancy. (Conditional recommendation, low quality evidence. Existing 
recommendation) [39].     
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AIM OF THE STUDY 
 
 
Accurate and rapid detection of either active and latent TB infection are critical for 
improving patient outcomes and decreasing TB transmission. Mycobacterial culture is 
generally considered the best available reference standard for TB diagnosis and is the first 
step in detecting drug resistance but it is a relatively complex and slow procedure. 
Rapid testing for Mtb infection and treatment of LTBI in targeted populations is an 
important strategy in TB elimination, thus, discriminating LTBI from active TB may be 
challenging for novel screening tests because it is currently not possible; the TST and  Mtb 
specific  IGRAs are still the main screening tools used for the diagnosis of TB infection 
and, although the newer IGRAs show some improvements over TST [52-54],  neither 
diagnostic test can differentiate between LTBI, active TB or past TB [42]. 
In view of this, this study was focused on improving TB diagnosis by developing a new 
blood test able to discriminate between active TB and LTBI according to the best 
cost/effectiveness ratio. 
In 2012 our group showed, for the first time, that out of a number of Mtb antigens tested 
including Ala-DH, ESAT-6, CFP-10, PstS1, HSP-X and antigen-85B, only Ala-DH 
induced IL-2 production, measured by an ELISpot assay, that could clearly distinguish 
children with LTBI from those with active TB [55]. Thus, this study wants to confirm the 
role of Ala-DH as a diagnostic tool in IL-2 ELISpot in a population of adult subjects too. 
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MATERIALS AND METHODS 
 
 
Patients and definition of study groups 
 
This study was performed on peripheral blood samples collected from patients with 
confirmed active TB, from subjects diagnosed with LTBI and from healthy donors, who 
were consecutively enrolled during the period between September 2014 and August 2016 
by the Careggi University Hospital, Florence, Italy. Subjects below 18, pregnant women, 
HIV/AIDS and all those people with any known immunocompromising condition (such as 
diabetes, haematological malignancies, end stage kidney disease and immunosuppressive 
therapy) were excluded from the study. None of the healthy patients had recent exposure to 
active pulmonary TB cases. 
Following the approval by the ‘‘Area Vasta Centro, Regione Toscana, Ethical Committee 
’’ (BIO 14.013), each patient, previously informed of the aim of the study, signed an 
informed consent. 
 All subjects were tested with TST (Sanofi Pasteur MSD SNC, Lyon, France) according to 
the Mantoux method [44] and with the IGRA test QFT-G-IT according to the 
manufacturer's instructions [45]. 
The subjects enrolled in the study were classified as active TB patients, LTBI patients or 
healthy people in accordance with the current guidelines [2, 40, 56]. 
 Active TB patients, in addition to TST positivity and a generally positive QFT-G-IT that 
can be negative in a certain number of cases, were detected through clinical, 
microbiological and radiological findings. The diagnosis confirmation required Mtb 
identification through fluorescence microscopy, PCR or cultural assays upon biological 
samples, such as sputum or BAL for respiratory diseases, tissue biopsies, drainage liquid or 
needle aspirates for extrapulmonary localizations. In particular, all samples were tested 
with auramin-rhodamine fluorescence microscopic examination to detect acid-alcohol 
resistant bacilli (BAAR); PCR-based methods like Artus Mtb PCR Kit (Qiagen, Venlo, 
Netherlands) and GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA) were used to 
identify the Mycobacterium strain and to detect rifampicine resistance; then mycobacterial 
specific solid and liquid culture media were used for the isolation of the infectious agent. 
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LTBI was diagnosed by a positive test for Mtb infection in persons without history of BCG 
vaccination or by both TST and IGRA positivity in BCG vaccinated subjects, provided the 
exclusion of active TB by medical history, clinical, radiologic, and microbiologic 
evaluations [45, 57, 58]. 
A subject without BCG vaccination and discordant results between TST and QFT-G-IT 
was attributed to his study group based on the TST result according to the Mantoux 
method that is still the standard test for LTBI diagnosis; however, IGRAs are 
recommended to confirm LTBI diagnosis in TST positive BCG vaccinated individuals [2, 
36, 52]. 
 Patients with assessed TST and/or QFT-G- IT positivity and CXR positivity and/or in the 
presence of cough (N = 97) were tested for Mtb identification through fluorescence 
microscopy, PCR and cultural assays on biological samples. The Mtb identification tests 
were not performed in subjects with negative TST and negative QFT-G-IT.  
Consequently, to the diagnosis, the 215 patients were classified as active TB cases (n = 
73), LTBI cases (n = 88) and healthy individuals (n = 54). (Table 1) summarizes data from 
the 215 patients enrolled in the study. 
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 Healthy            
N (%) 
LTBI              
N (%) 
Active TB       
N (%) 
 
54 (25) 88 (41) 73 (34) 
Age 
Median (IQR) 46 (32-63) 46 (35.5-65) 39 (31-61.5) 
 
Immigrated 27 (50) 45 (51) 48 (66) 
 
BCG 
vaccinated 
21 (38.8) 38 (43.2) 32 (43.8) 
 
       TST (mm) 
<5 54 (100) 0 (0) 0 (0) 
≥5 and <10 0 (0) 5 (5.8) 0(0) 
≥10 and <15 0 (0) 13 (14.7) 8 (11) 
≥15 0 (0) 70 (79.5) 65 (89) 
 
       QFT-G-IT 
Negative 50 (92.65) 5 (5.7) 4 (5.48) 
Positive 3 (5.5) 80 (90.9) 68 (93.15) 
Indeterminate 1 (1.85) 3 (3.4) 1 (1.37) 
Fluorescence microscopy 
Positive Not performed 0 (0) 42 (57.5) 
Negative Not performed 24 (100) 31 (42.5) 
PCR- based tests 
Positive Not performed 0 (0) 73 (100) 
Negative Not Performed 24 (100) 0 (0) 
Mtb isolation from culture 
Positive Not performed 0 (0) 73 (100) 
Negative Not performed 24 (100) 0 (0) 
Table 1. Characteristics of the 215 subjects divided according to the diagnosis in the three study 
groups 
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Reagents 
 
Lymphoprep was purchased from Fresenius Kabi Morge AS (Axis-Shield, Oslo, Norway), 
RPMI 1640 medium from Biochrome (Leonorenstr, Berlin), L-glutamine from Euroclone 
(Italy), betamercaptoethanol from Sigma-Aldrich (Darmstadt, Germany) Na-pyruvate and 
Non-essential aminoacids from Thermofisher scientific (Waltham, MA, USA), 
penicillin/streptomycin from PAN biotech (Aidenbach, Germany), fetal bovine serum 
(HyClone, GE Helathcare Life Science, Utah, USA). 
 LIOSpot® TB (LIONEX GmbH, Braunschweig, Germany) is an anti-human IL-2 
ELISpot kit containing M. tuberculosis ESAT-6, CFP-10 and Ala-DH recombinant 
antigens, all produced at LIONEX to a purity of more than 98% and endotoxin free; 
Phytohaemagglutinin mitogen (PHA) was used as a positive control. 
 
 PBMCs isolation 
 
PBMCs were isolated from blood samples of each enrolled patient, within 8 hours after 
venipuncture to ensure cell activity, by Ficoll-Hypaque density gradient centrifugation. 
Briefly, blood was layered on top of Lymphoprep, density gradient of 1.077 g/mL, and 
centrifuged at 800 x g for 25 minutes at room temperature (15-25°C) without brake. 
PBMCs layer was harvested and washed two times in PBS, pH 7.4. Cells were counted 
using the Burker chamber and then transferred into RPMI 1640 complete medium 
(supplemented with L-glutamine 1%, beta-mercaptoethanol 1%, Na-pyruvate 1%, non-
essential aminoacids 1%, penicillin 50.000U and streptomycin 50 mg), with 5% fetal 
bovine serum to obtain a concentration of 2.5x10⁶ PBMCs/ml. Both freshly prepared and 
cryopreserved cells may be used in this assay. 
 
Anti-human IL-2 ELISpot assay 
 
The enzyme-linked immunospot (ELISpot) assay is a highly sensitive and specific method 
available for monitoring T and B cell response, permitting the ex vivo identification of cells 
actively secreting signalling proteins or antibodies after stimulation wit h appropriate 
stimulus in vitro. The T cell ELISpot assay has the lowest detection threshold among the 
assays viable for detection of T cell responses. With ELISpot assay it is possible to detect 
one specific cell out of 100 000 irrelevant cells, making this method much more sensitive 
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than traditional ELISA application because the secreted protein is captured directly on to 
the well of an ELISpot plat before having the chance to be diluted in the culture 
supernatant, degraded by proteases or captured by receptors on adjacent cells. The ELISpot 
assay is very similar to ELISA and is based on the same immunochemical ‘sandwich’ 
principle. The major difference is that an ELISpot is a combination of both an 
immunoassay and bioassay because living cells are cultured directly in the wells of the 
ELISpot plate. In this assay, cells are cultured on a surface coated with a specific capture 
antibody in the presence or absence of stimuli; the cytokines, secreted by the T cells after 
stimuli response, will be captured by the specific antibodies in each well. After an 
appropriate incubation time, cells are removed, and the secreted molecule is detected using 
a detection antibody in a similar procedure to that employed by the ELISA. The detection 
antibody is either biotinylated and followed by a streptavidin-enzyme conjugate or the 
antibody is directly conjugated to an enzyme. By using a substrate with a precipitating 
rather than a soluble product, the end result is visible as spots on the surface (Fig. 8). A 
single cell forms a coloured ‘footprint’ (spot) on the bottom of the well representing its 
secretory activity. The frequency of spot forming cells can be quantified from the number 
of spots in the well and cell input. The term ‘spot-forming cells or SFC’ is used as a 
quantitative measure for number of cytokine or antibody secreting cells in the ELISpot 
assay. Each spot corresponds to an individual cytokine-secreting cell. ELISpot can be used 
to discriminate between subsets of activated T cells. For example, Th1 cells are 
characterized by their production of IFN-γ, IL-2, and TNF-α, whereas Th2 cells produce 
other cytokines such as IL-4, IL-5, and IL-13. Major advantages of ELISpot assay is easy 
performance, its potential for high throughput screening and no requirement for expensive 
instruments. 
 
 
 
Figure 8. ELISpot step-by-step guide. The image shows the sequence of different steps to 
perform an ELISpot: 1) Antibody coating; 2) Cell incubation; 3) Cytokine capture; 4) Detection 
antibodies; 5) Streptavidin-enzyme conjugate; 6) Addition of substrate; 7) Analysis. 
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In our study was used the LIOSpot ®TB anti-human IL-2 ELISpot kit containing a 96-well 
plate coated with anti-human IL-2 for detection of IL-2 production by T cells stimulated 
with three Mtb antigens, like ESAT-6, CFP-10 (also used in IGRAs) and Ala-DH. 
First we added the positive control (PHA) and the negative control (medium) as single 
determinations and the three different antigens ESAT-6, CFP-10 and Ala-DH in double 
determination (5μg/ml) (Table 2); then PBMCs from each patient were seeded in order to 
have 2.5x10⁵ cells per 0.1ml/well, working under sterile conditions. 
 
A Negative control:only medium 
B Ala-DH 
C Ala-DH 
D ESAT-6 
E ESAT-6 
F CFP-10 
G CFP-10 
H Positive control (mitogen): PHA 
 
Table 2.  Map of antigens used in IL-2 ELISpot plate. 
 
                                  
The plate was incubated in a humidified incubator at 37°C, 5% CO2 for 16-24 hours: 
during incubation time the antigen will activates specific T cells to release IL-2 that will be 
captured by the antibody at the bottom of the well. 
After the incubation time wells content was discarded and the plate was washed five times 
with a wash buffer (PBS 0.05% Tween-20) before adding the anti-human IL-2 biotinylated 
detection antibody to each well. After one hour of incubation, wash steps were repeated, 
and the conjugated horseradish peroxidase (HRP)-streptavidin solution was then added. 
The advantage of using HRP is its fast turnover rate (spots develop fast), The plate was 
incubated again for one hour at room temperature (RT) and, after being washed as already 
described, TMB (3,3ʹ,5,5ʹ-Tetramethylbenzidine) substrate solution was dispensed into 
each well and incubated for ten minutes at RT in the dark, until spots were visible. The 
HRP substrate forms intense coloured spots but may be bleach in short period of time 
when stored in daylight. Therefore, plates should be protected from light  and moisture 
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during storage at room temperature. Following the development of spots, the wells' content 
was discarded, and a stop solution was used. The plate was dried and the number of SFC 
(spot forming cells) was counted by an automated ELISpot reader using the AID ELISpot 
Software Version 3.2.3 (Fig. 9). 
The SFC count in PHA positive control wells should be more then 50 or show saturation to 
39 confirm cellular functionality and vitality. In the negative control it would be expected 
to have few or no spots; the number of SFC in the negative control is subtracted from the 
SFC mean value of the wells containing the ESAT-6, CFP-10 and Ala-DH antigens. 
Results were expressed as number of SFC per million of PBMCs. 
 
 
Figure 9.  ELISpot reader. 
 
 
Statistical analysis 
 
Descriptive statistics were used for the calculation of absolute frequencies and percentages 
for qualitative data, as well as for mean, median (IQR), and standard deviation of 
quantitative data. All distributions of ELISpot test results for healthy patients, LTBI 
subjects or active TB patients were compared using the Mann-Whitney inferential test or 
the Student t-test. P <0.05 was considered statistically significant. 
Test performance in terms of sensitivity (ability of the test to identify the true positive 
subjects) and specificity (ability of the test to identify the true negative subjects) was 
evaluated for each antigen by a ROC (Receiving Operating Characteristic) curve, the 
elective validation method of a quantitative diagnostic test in a population. The proportion 
of patients correctly diagnosed, that is the test accuracy, is proportional to the area under 
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the curve (AUC), which can assume values between 0.5 (50% accuracy) and 1 (100% 
accuracy). According to the classification proposed by Swets the test is not accurate for 
AUC = 0.5, the test is poorly accurate for 0.5 <AUC≤ 0.7, the test is moderately accurate 
for 0.7 <AUC≤ 0.9, the test is highly accurate for 0.9 <AUC< 1 and the test is perfect for 
AUC = 1 [59]. The ROC curve also allows to identify the best cut off value that maximizes 
the difference between true positive subjects and false positives ones; it is the best 
threshold value for anti-human IL-2 ELISpot result relative to each specific antigen 
(ESAT-6, CFP- 10 and Ala-DH) in order to discriminate between patients with active TB 
and subjects with LTBI. 
To maximize both sensitivity and specificity, the Youden's index (= Sensitivity- [1- 
Specificity]) can be applied. 
Finally, the correlation between the ELISpot diagnostic test for each antigen and the 
diagnosis performed on each patient using the current methods was calculated by Cohen's 
Kappa coefficient according to which there would be slight concordance for the value of k 
= 0.2, poor concordance for the value of K in the range 0.2-0.4, moderate concordance for 
k value in the range 0.4-0.6, substantial concordance for k value in the range 0.6-0.8, good 
concordance for k value in the range 0.8-1. 
Statistical analysis was performed with SPSS for Windows software version 20.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
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RESULTS 
 
 
Two hundred and fifteen subjects were enrolled in this study: 73 patients with active TB, 
88 with LTBI and 54 as uninfected controls. We performed LIOSpot® TB according to kit 
manual on PBMCs isolated from a blood sample of every participant by stimulation with 
Mtb antigens such as ESAT-6, CFP-10 and Ala-DH (Fig. 10) ; the T cell specific response 
to each antigen was evaluated in terms of IL-2 production (Table 3). 
Mann-Whitney inferential test or Student t-test were used to compare ELISpot results for 
IL-2, as SFCs per million PBMCs, between healthy patients, LTBI subjects and active TB 
ones referring to each tested antigen. Comparing the results of infected and non-infected 
there were significant differences for all the antigens (p≤0.0001); similarly, comparing the 
results of patients in LTBI and the group of active TB patients there were significant 
differences for all three antigens too (p≤0.0001) (Table 3). 
 
 
Healthy 
(n=54) 
Latent TB 
(n=88) 
Active TB 
(n=73) 
P     
(Healthy vs 
infected) 
P 
(Latent vs 
active disease) 
Ala-DH 
0 7.5 280 
p≤0.0001 p≤0.0001 
(0;0) (2.5;10) (85;1120) 
ESAT-6 
2.5 180 392.5 
p≤0.0001 p≤0.0001 
(0;17.5) (30;340) (140;1300) 
CFP-10 
0 192.5 480 
p≤0.0001 p≤0.0001 
(0;15) (77.5;660) (325;1590) 
 
Table 3. IL-2 based ELISpot test  results for the 215 enrolled patients. IL-2 based ELISpot test 
results for the 215 enrolled patients, clustered according to the diagnosis. The values are expressed 
as mean and interquartile range of SFC per million PBMCs. 
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Figure 10. IL-2 ELISpot results. Example of test results as SFC for a healthy person, a LTBI 
subject and an active TB patient. Yellow highlighted the Ala-DH SFC. 
 
 
 
ROC curve analysis was performed for each antigen in order to establish the best cut off of 
the ELISpot test for IL-2 in discriminating between LTBI and active TB. Considering the 
response to Ala-DH antigen, a best cut off value of 12.5 SFC per million PBMCs to have a 
96% sensitivity and 100% specificity was established. The area under the ROC curve was 
0.971 (IC 95%: 0.939-1), so the test was highly accurate in correctly diagnosing subjects 
with active disease and those with latent infection. For the ESAT-6 antigen, with a best cut 
off of 71.25 SFC per million PBMCs, a sensitivity of 86% and specificity of 36% was 
obtained. The area under the ROC curve was 0.713 (IC 95%: 0.632-0.794), the test is 
moderately accurate. Finally, the best cut off for CFP-10 was 231.25 SFC per million 
PBMCs, with AUC = 0.693 (IC 95%: 0.611-0.774); The test had a low accuracy, with 
sensitivity of 80% and specificity of 54% (Fig. 11) 
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Figure 11. Receiver operator characteristic (ROC) curve. A ROC curve (blue line) plot of the 
LIOSpot® TB is shown, illustrating sensitivity and specificity for Ala-DH (A), ESAT-6 (B) and 
CFP- 10 (C) to discriminate subjects with active TB from LTBI ones. AUC is the area delimited by 
the ROC curve and the green reference line. 
 
 
Once the best threshold value for the ELISpot IL-2 result was set for each specific antigen 
to discriminate between subjects with active TB and subjects with LTBI, the correlation 
between ELISpot and TST, that is still the standard test for Mtb infection diagnosis, was 
assessed for every antigen by computing The Cohen’s Kappa coefficient and interpreting 
the data as described above. 
The concordance between the ELISpot test for IL-2 and the TST test for all the results  
obtained in the 215 patients with Ala-DH, ESAT-6 and CFP-10 is: 92.56% (k = 0.82 very 
good concordance), 77.2% (k = 0.53, moderate concordance) and 63.7% (k = 0.35, poor 
concordance) respectively (Table 4). 
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TST vs ELISpot Ag 
Concordance(%) 
 Cohen’s Kappa (k) 
TST vs ELISpot Ala-DH 92,56%, k=0,82 
TST vs ELISpot ESAT-6 77,2%, k=0,53 
TST vs ELISpot CFP-10 63,7%, k=0,35 
 
Table 4. Concordance between TST and IL-2 based ELISpot for each antigen in the study, for all 
the enrolled subjects. 
 
 
The concordances between the different assays are shown in (Table 5). The five patients 
with indeterminate Quantiferon were excluded by this statistical analysis. ELISpot test for 
IL-2 and the QFT-G-IT test for all the results obtained in the 210 patients with Ala-DH is 
57.1% (k = 0.25 poor concordance), with ESAT-6 is 79.5% (k = 0.57 moderate 
concordance) and with CFP-10 is 71% (k = 0.44, moderate concordance). These results are 
in agreement with results presented in this report since not all QFT-G-IT positive subjects 
were TB patients. 
 
          QFT-G-IT vs ELISpot Ag 
Concordance(%) 
 Cohen’s Kappa (k) 
           QFT-G-IT vs ELISpot Ala-DH 57.1%, k=0.25 
          QFT-G-IT vs ELISpot ESAT-6 79.5%, k=0.57 
         QFT-G-IT vs ELISpot CFP-10 71.0%, k=0.44 
 
Table 5. Concordance between QFT-G-IT and IL-2 based ELISpot for each antigen in the study, 
for all the 210 enrolled subjects. 
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DISCUSSION 
 
 
Current TB diagnostics assays have limitations because they do not differentiate between 
LTBI and active TB. There is a great necessity for profiling biomarkers in addition to IFN-
γ to improve TB diagnosis to facilitate quick and correct treatment implementation. This 
study aimed to identifying biomarkers of TB infection that are significantly different 
between active and latent status. During LTBI, Mtb lives in a non-replicating state, 
enclosed into the granuloma structure, as long as the host remains immunocompetent; in 
this period the bacillus still maintains the ability to reactivate and produce active disease 
when the host immune response is impaired [12, 60]. 
Studying gene expression profiles and proteomic analysis in both active and quiescent Mtb, 
a number of genes that are differently regulated during the latency phase have been found, 
in comparison to those expressed during active infection [27, 61], five proteins more 
abundant under low-oxygen conditions were identified from several lysates of Mtb: 
Rv0569, Rv2031c (HspX), Rv2623, Rv2626c, and Rv3841 (BfrB). In Mtb culture filtrates, 
two additional proteins, Rv0363c (Fba) and Rv2780 (Ald), were found in increased 
amounts under oxygen limitation [61]. Different antigens of latency are currently known, 
several of them were identified in the DosR-regulon [62-64]. Another gene, Rv2780, that 
encode Ala-DH, was found to be over- expressed during the Mtb dormancy phase, under 
nutrient starvation and lack of oxygen regimes [32, 61, 65]. 
Mtb Ala-DH catalyzes reversible conversion of pyruvate to alanine, and glyoxylate to 
glycine concurrent with the oxidation of NADH to NAD [66] to maintain the optimal 
NADH/ NAD ratio during anaerobiosis in preparation of eventual regrowth, and during the 
initial response during reoxygenation [32]. 
Thus, Mtb Ala-DH was thought to be a useful tool to discriminate between LTBI and 
active TB [67] and our previous study demonstrates that this antigen is able to stimulate 
IL-2 production  in active TB but not in LTBI children; in that study we evaluated the 
performances of INF-γ and IL- 2 based ELISpot assay in children at risk for TB used an 
array of Mtb specific antigen (ESAT-6, CFP-10, TB 10.3, Ala-DH, Ag85B, PstS1,HspX 
(16 kDa) protein): the responses of 6 antigens in children with LTBI and active TBI were 
compared and their data  revealed that IL-2 responses to Ala-DH antigen were significantly 
different between the children with active TB and the healthy control group but not 
between LTBI subjects and healthy ones [55]. 
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Given these findings, in the present study we aimed to confirm our result in an adults 
cohort tested with the LIOSpot® TB kit, an ELISpot assay developed to detect IL-2 
production by T cells stimulated with three Mtb antigens, like ESAT-6, CFP-10 (also used 
in IGRAs) and Ala-DH. 
Cytokines play an important role in cell mediated immune responses to Mtb infection. The 
IFN-γ production by activated T cells has been widely considered to play a crucial role in 
protection against Mtb infection [12]. The choice of setting the LIOSpot® TB assay on IL-
2 cytokine production is due to the fact that several studies have demonstrated that the IL-2 
response to Mtb-specific antigens is significantly higher in active TB patients, suggesting 
that IL-2 could be a potential infection biomarker [68, 69]. 
Antigen-specific memory T-cells can be subdivided into effector memory T-cells (TEM) 
and central memory T-cells (TCM) [70]. TEM cells express receptors that enable them to 
migrate to the inflamed peripheral tissues and differentiate directly into effector cells. IL-2 
is promoting T-cell replication and is essential for cellular immunity and granuloma 
formation. Although IFN-γ is predominantly produced by TEM, IL-2 is mostly produced 
by TCM, thus, it is related to ancient exposure [71, 72].  
The secretion of IL-2 is secreted from cells also secreting IFN-gamma in both the early and 
the later stages of infection and when the antigen load has declined. Dual IFN-gamma /IL-
2-secreting cells in active phase of TB can support their own expansion because IL-2 is a 
potent T cell growth factor. The presence of these cells inactive TB when the antigen load 
is high may therefore suggest their involvement in the initiation phase of the immune 
response. IL-2 in LTBI or when the antigen load is reduced or cleared may reflect its 
function in the termination of T cell responses. This proposed signalling function augments 
the growth and survival of regulatory T cells that control inflammatory responses [73]. 
A study conducted in Republic of Korea by Eun-Jeong Won et al. [67] measured 39 
different cytokines in IGRA supernatants by Luminex assay: eight biomarkers (GM-CSF, 
IFN-γ, IL- 1RA, IL-2, IL-3, IL-13, IP-10, and MIP-1b) in the Mtb-infected group were 
significantly different from those of the healthy controls. The same study design was 
conducted among 19 active TB patients, 8 TB-negative individuals (controls) and 16 LTBI 
non-human immunodeficiency virus infected individuals in Nairobi, Kenya. Excess 
supernatants from the IGRA test were used to measure immune analytes using a luminex 
assay; the study suggested that IL-17F, MIP-3α, IL-13, IL-17A, IL-5, IL-9, IL-1β and IL-2, 
in addition to IFN-γ, could identify and uniquely discriminate between TB states [74] 
Despite the low sample size limitation, this study was able to identify putative biomarkers 
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of TB disease in Kenyans that warrant further investigation. 
In another study conducted in China by Jing Wu et al. [75] the cytokine production by 
PBMCs after Mtb PPD stimulation was evaluated by luminex assay: the levels of IL-2, IL-
10, IFN-γ, IP-10 and TNF-α were significantly higher in LTBI group than in active TB 
group, endorsing that cytokines such as IL-2 and IL-10 may serve as biomarkers for 
distinguishing healthy from infected patients and active TB from LTBI subjects too. 
 A further Chinese study setted a novel electrochemiluminescence (ECL)-sensing platform 
for the precise analysis of multiple LTBI markers IFN-γ and IL-2: the ECL intensity 
depended linearly on the content of IFN-γ and IL-2 and can be used to detect IFN-γ and IL-
2 associated with LTBI [76].  
Consistent with several other studies [68] is clear that the IL-2/IFN-γ ratio have the 
potential to be used as diagnostic biomarkers to distinguish between LTBI and active TB. 
According to these findings, LIOSpot® TB was set as an anti˗human IL-2 ELISpot assay 
able to detect IL-2 production after PBMCs stimulation with ESAT-6, CFP-10 and Ala-DH 
of Mtb. 
In our study, all the healthy subjects showed no significant production of IL-2 (SFC per 
million of PBMCs) in response to T cell stimulation by the three different antigens: Ala-
DH (0: 0-0), ESAT-6 (2.5: 0-17.5) and CFP-10 (0: 0-15). Furthermore, it is of note that 
none of the 21 BCG-vaccinated healthy subjects gave positive IL-2 responses to Ala-DH. 
The LIOSpot® TB detected a significant production of IL-2 after stimulation with ESAT-6 
(392.5: 140-1300), CFP-10 (480: 325-1590) and with Ala-DH (280: 85-1120) in 73 
patients group with active TB. Among people in the LTBI group, despite the smaller but 
substantial production of IL-2 in response to ESAT-6 and CFP-10 stimulation (180: 30-340 
and 192.5: 77.5-660 SFC per million of PBMCs respectively) compared to active TB 
cases, Ala-DH induced a very low amount of IL-2 production by stimulated T cells (7.5: 
2.5-10 SFC per million of PBMCs). 
Even though comparing the LIOSpot® TB results for each tested antigen between 
uninfected and infected subjects and between people with LTBI and active TB, all the 
differences were significant (p< 0.0001), the ROC analysis demonstrated a high accuracy 
of the test only for Ala-DH: with a cut off value of 12.5 SFC per million PBMCs, the Ala-
DH ROC curve conferred 96% sensitivity and 100% specificity to the test. Thus, the 
LIOSpot® TB test is highly accurate and is able to make a differential diagnosis between 
subjects with active TB and those with LTBI. 
For the ESAT-6 antigen, with a best cut off value of 71.25 SFC per million PBMCs, a 
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sensitivity of 86% and specificity of 36% was obtained. Finally, the best cut off value for 
CFP-10 was 231.25 SFC per million PBMCs, with sensitivity of 80% and specificity of 
54%. 
Despite the low specificity, these thresholds confer to the LIOSpot® TB the ability to 
detect true tuberculosis infection. Limitation of our present study include has done in 
single-center study. Unclear if test would be practical in low-resource settings. 
Overall, the present study demonstrates that the LIOSpot® TB test is a very useful 
diagnostic tool to discriminate between LTBI and active TBI. Accordingly has a diagnostic 
value for individuals with active TB. However, further prospective studies are needed to 
monitor the ELISpot assay of IL-2 responses to Ala-DH among patients exposed to TB 
infection  in many center study. 
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INTRODUCTION 
 
Systemic lupus erythematosus (SLE), commonly referred to as “lupus”, is a multifactorial 
chronic and multisystem autoimmune disease of unknown causes with a highly 
heterogeneous pattern of clinical and serological manifestations, and a relapsing and 
remitting course. The pathogenesis most likely involves a complex interaction among gene 
susceptibility, hormonal influences and environmental factors resulting in an irreversible 
loss of immunologic self-tolerance. Autoantibodies (auto-Abs) production, immune 
complex (IC) deposition, complement activation and consequent dysregulation of the 
inflammatory response, leading to the induction and maintenance of the disease and 
resulting in damage and destruction of multiple organs. The pathogenic process is 
characterized by a sequence of events, which take a long time before ending into overt 
clinical manifestations [1, 2].  
SLE can be severe and is associated with increased mortality from a variety of causes, 
including disease activity, in particular when vital organs or systems are involved, and 
treatment complications. Recent studies demonstrated that disparities according to age, sex, 
race/ethnicity, and socio-economic status are determinants that may affect the frequency 
and progression of SLE. 
SLE is a predominately female disease and more than 90% of cases of SLE occur in 
women in childbearing age. However, 10-20% of patients have onset of disease in 
adolescence or younger named paediatric SLE (pSLE) [3]. On the other hand, Late-onset 
lupus, (i.e., after the age of 50 years) is reported to occur in 3-18% of patients typically 
showing a lower disease activity, including less incidence of nephritis, and less organ 
damage, but higher pulmonary manifestations. However, the overall outcome is poorer in 
patients with late-onset disease, probably because of increased comorbidity situations [4]. 
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The incidence is higher in women during reproductive years; however, people of all ages, 
genders, and ancestral backgrounds are susceptible. The female-to-male incidence ratio 
varies with age as it approximates 1:1 during the first decade of life, followed by a sharp 
increase to 9:1 during the fourth decade and then a decline in subsequent years before 
increasing again during the seventh to the eighth decade [5]. Overall, the female-to-male 
ratio is 7-15:1 in adults and 3-5:1 in children [6]. Several studies support that the female 
predominance in SLE may result from a complex interaction among sex hormones, 
genetics and epigenetic factors, and gut microbiota [7]. The frequency of Klinefelter’s 
syndrome (47, XXY), often subclinical, is increased in men with SLE by 14-fold compared 
with its prevalence in men without SLE. Prevalence of Klinefelter’s syndrome in males 
with SLE has suggested a gene-dose effect at the X chromosome level. The presence of 
two X chromosomes increases the severity of SLE [8]. 
Notably, the time of disease onset, clinical manifestations, comorbidities, and the overall 
disease course differ considerably between male and female patients with SLE. Males tend 
to show more severe course of the disease with important clinical manifestation such as 
nephritis and serositis [9]. 
SLE, present across ethnicities, is more prevalent in non-Caucasians. While the prevalence 
in Europe and USA is higher in people of African descent, in USA the incidence of SLE in 
Afro-American females is >2.5 times higher than in white females with more sever disease 
and poorer clinical outcomes [10]. 
SLE is a worldwide disease, and in many countries, its prevalence approximates or even 
exceeds 80-100 per 100,000 adults. The estimate of the incidence and the prevalence of 
SLE, even within the same country or region, presented a high variability in various 
reports. Such a variation may be due to dissimilarities in the genetic make-up and 
environmental exposures of the population under study, although methodological 
differences are also critical. There are two well-conducted studies carried out by the 
Centres for Disease Control and Prevention (CDCP) in USA, that estimated the frequency 
of SLE in Michigan [11] and in Georgia [12] on the basis of data collected from 2002- 
2004, a period that reported very similar incidence (5.5 and 5.6 per 100,000 person-years) 
and prevalence (72.8 and 73.0 per 100,000) rates. Two other studies also provided 
estimates of the incidence and prevalence of SLE among residents of the New York 
(Manhattan) (4.6-6.2 per 100,000  person-years  and  62.2-73.8  per  100,000  person-
years,  respectively)  [13]  and  the San Francisco (California) (4.6 per 100,000 person-
years and 84.8 per 100,000 person-years, respectively) [14] counties. Collectively, more 
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recent estimates of SLE frequency tend to be increased as compared with previous ones, at 
least in USA. Importantly, these data are generally considered as more accurate, because 
they originate from studies that were better designed using more strict case definitions, 
broader case-finding methodology and were corrected for possible case under-
ascertainment. The prevalence of SLE among East Asians is higher than among Europeans 
[15]. 
Ethnicity has been identified as an important modifier of SLE outcome with higher 
mortality rates was found in Native and Afro-Americans than in Caucasians, Asian, and 
Hispanics. The study was based on data in CDCP database that were extracted from 
females death certificates issued between 2000 and 2015 in USA [16]. 
Furthermore, Tektonidou et al. [17] reported that during 2008-2016, the 5, 10, and 15 year 
survival rates in adult patients with SLE were 0.95, 0.89, and 0.82, in high-income 
countries, respectively, compared to 0.92, 0.85, and 0.79, in low/middle-income countries 
respectively. 
Non-white race, and low socio-economic status are associated with more severe forms of 
the disease including increased rates of renal involvement. SLE is associated with a shorter 
life expectancy than in the general population. Standardized mortality ratios (SMR) of 2.4, 
comparable to diabetes, have been reported [18]. 
To date numerous SLE susceptibility genes have been identified. A sibling risk ratio of 
approximately 30 in SLE illustrates a strong genetic influence and the fact that 
observational studies have identified many families with multiple cases of SLE and other 
autoimmune conditions suggests the potential for shared genetic predisposition [19]. 
Studies showed that monozygotic twins have a ten-fold higher risk to develop SLE than 
dizygotic twins and a clear aggregation of SLE in families. This together with the findings 
in large-scale genome-wide association studies (GWAS) has allowed the recognition of 
>80 loci associated with SLE leads to the formation of key proteins involved in innate and 
adaptive immunity, each one contributing to a small increased risk and implicating a strong 
genetic background for SLE. More than 50% of lupus susceptibility genes are linked to the 
interferon (IFN) system [20]. In addition, gene loci involved in the NFkB signalling 
pathway, DNA degradation, apoptosis, phagocytosis, neutrophil, and 
monocyte/macrophage functions and signalling have been identified. The most pronounced 
association, however, was found for HLADR2/DR3, followed by BLK and PTPN22 
involved in T and especially B cell activation and therefore adaptive immunity. Regulation 
of the gene expression appears to play a role in lupus pathogenesis. Each cell type might 
48  
have a specific and dynamic epigenetic profile. The interaction between the host and the 
presumed environmental factors resurfaces and suggests that they may directly interact at 
this level [21]. The certain miRNAs in SLE, miRNA (miR)-30a in B cells has been shown 
to decrease the expression of Lyn as central protein tyrosine kinase of B cell receptor 
signalling. The study arrived at the hypothesis that low levels of Lyn expression in SLE are 
due to an increased expression of miR-30a, which may facilitate B cell proliferation and 
antibodies (Abs) production [22]. 
Many sex hormones (including oestrogens, progesterone, androgens, and prolactin) 
affecting the susceptibility and development of SLE, may also play a role as triggers or 
protectors in SLE development. Studies in human populations and experimental models 
have indicated an elevated risk of SLE associated with the exposure to estrogens whereas 
progesterone and testosterone appear to play a protective role via counteraction of 
estrogens effects. Other sex hormones such as prolactin remains controversial. 
The potential role of estrogens in autoimmune diseases has been extensively investigated, 
particularly for SLE. In genetically predisposed individuals, estrogens increase the risk of 
disease and have a pathogenic role in SLE. The pathogenic mechanisms may involve the 
production of type 1 (T1) IFN, survival of auto-reactive B cells and production of 
pathogenic immunoglobulin (Ig) G auto-Abs, and/or differentiation of CD4+ Th cells. 
Enhanced expression of T1 IFN-inducible genes has been detected in SLE, and this so-
called “IFN signature” has been shown to play a critical role in the pathogenesis of SLE 
and is associated with active disease. T1 IFNs also increase estrogens signaling in immune 
cells by provoking the expression of ER-a, thereby contributing to SLE development and 
progression. Estrogens can also enhance the production of anti-double stranded DNA (anti-
dsDNA) antibody and IgG or IgM by peripheral blood mononuclear cells (PBMCs) and 
serum, which enhances the disease severity causing flare-ups. Estrogens were also shown 
to exacerbate lupus disease severity via an ERa- independent mechanism along with other 
immune effects contributing to the lupus pathogenesis, including modulation of Toll-like 
receptor (TLR) pathways, dendritic cells (DCs) development, or E2-TWEAK signalling. 
These mechanisms might also contribute to the pathogenic mechanism of SLE, primarily 
affecting women [23]. 
Progesterone has been suggested to play an important protective role against SLE disease 
activity, counteracting the effects of estrogens. Progesterone has immuno-modulatory 
effects, it impairs IRF-7 activation in plasmacytoid dendritic cells (pDCs), which regulate 
the TLR-mediated decreased production of IFN-, a major source of T1 IFN, through 
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depot medroxyprogesterone acetate (DMPA), thereby ameliorating the IFN signature and 
consequently SLE disease activity. Moreover, progesterone decreases the IgM to IgG class 
switch recombination via suppressing the transcription of activation induced cytidine 
deaminase (AICDA). High levels of progesterone will induce a T helper (Th) 2-type 
immunologic response and suppress a Th1-type one via inhibiting interleukine (IL)-12 
signaling in SLE. Meanwhile, there is a decrease in mortality, glomerulonephritis and Th1-
related auto-Abs production after DMPA treatment in NZB/NZW mice, which suggest that 
progesterone may have therapeutic benefit for SLE patients [24].  
Androgens may play an important protective role in the pathogenic mechanisms 
contributing to the development of SLE. Similar to progesterone, androgens target key 
immune pathways that can protect against SLE by counteracting the effects of estrogens. In 
particular, androgens down- regulate the expression of Ifi202 gene, which in turn decreases 
the production of T1 IFN. Compared with estrogens, androgens may enhance checkpoints 
for the auto-reactivity of B cells. Androgens decrease the Th1 differentiation of CD4+ T 
cells via inhibiting IL-12 signaling, which in turn mitigates CD4+ responses in autoimmune 
disease. Androgens also appear to modulate the accumulation of Gr1+CD11b+ cells in male 
mice, CD11b+ cells were shown to over-express DHT-regulated genes and colony-
stimulating factor 3 receptor, which was identified to influence the development of lupus 
and rheumatoid arthritis (RA) [25].  
Environmental factors, such as exposure to silicates, smoking and alcohol consumption, 
UV light, certain medications, vitamin D deficiency, viral infections, and estrogens are 
considered potential risk factors in the development of lupus. There is evidence for silica 
exposure [26] and a likely association for smoking and alcohol consumption [27] as 
contributors to SLE development. Vitamin D deficiency was found in most SLE patients 
[28]. As such, the role of vitamin D and SLE is complex. There is an association between 
vitamin D receptor single-nucleotide polymorphisms and a higher long-term cumulative 
damage in SLE has been reported [29]. Interestingly, vitamin status and CYP24A1 gene 
polymorphisms can have a combined role in the transition from incomplete to complete 
SLE, and this association is not confounded by the number of the American College of 
Rheumatology (ACR) classification criteria or exposure to sun at baseline [30].  
The sun exposure, on the other hand, leads to a higher serum vitamin D concentration, that 
might be protective, but UV light exposure is also a risk factor for the induction of SLE 
and patient deterioration. UV light is known to aggravate pre-existing skin manifestation 
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and can cause severe lupus flares with a plausible pathogenic mechanism: UV light 
exposure induces increased apoptosis of keratinocytes, followed by a prolonged exposure 
of self-antigens (Ags) due to known clearance defects that subsequently causes 
precipitation of immune complexes (ICs) in the skin (‘lupus band’) resulting in an initial 
state of inflammation [31]. 
Bacterial and viral infections, such as EBV, CMV, parvovirus B19, human endogenous 
retroviruses and others, have been implicated in the development of SLE where these 
agents apparently ‘kick-start’ the immune activation and give rise to chronic inflammation. 
Molecular mimicry mechanisms involved in this ongoing autoimmunity process. Infections 
have been implicated in SLE for a long time; this is largely based on indirect associations. 
A number of studies have suggested a correlation of Epstein-Barr virus seroprevalence 
(anti-viral capsid antigen IgG) with SLE (OR 2.08) [32]. The Epstein Barr Virus Antigen 1 
(EBNA-1) contains regions that are homologous to sequences of self-proteins such as 
Ro60 kDa and snRN. In SLE, McClain and colleagues could detect anti- EBNA-1 prior to 
the detection of anti-Ro. This suggests that EBV infection started with anti-EBNA-1 Abs 
production and due to similarities to Ro antigen, ‘switched’ to anti-Ro Abs production, 
probably after Ro60 kDa exposure due to apoptosis induced by UV light. This study 
demonstrated that anti-Ro Abs cross-react with EBNA-1 [33]. Bacterial infections 
contribute to SLE pathology through similar mechanisms. In SLE, endotoxins stimulation, 
such as lipopolysaccharides (LPS) of gram-negative bacteria displayed a substantial 
overlap demonstrating that they can in part mimic T1 IFN signature seen in the disease 
[34].  
Various dietary factors have been proposed to play a role in SLE pathogenesis through 
epigenetic changes (e.g., affecting DNA methylation) and/or interplay with the gut 
microbiota [35]. 
 The composition of gut microbiome is influenced by various factors such as genetics, sex 
hormones, diet, drinking water, and the use of antibiotics and probiotics. Hevia et al. [36] 
revealed lower levels of fecal Firmicutes/Bacteroidetes ratio in SLE patients than in 
healthy individuals. Importantly, intestinal dysbiosis has been linked to a disrupted balance 
between regulatory and pathogenic Th17 cells in SLE [37]. More recent data support the 
hypothesis of “leaky” gut epithelium in SLE, which leads to translocation of gut 
pathobionts, e.g. Enterococcus gallinarum, to the liver and lymph nodes, thus increasing 
the expansion of autoreactive T cells [38]. 
Psychosocial factors (including alexithymia, depression, anxiety, negative emotions, 
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perceived stress) affect the susceptibility and development of SLE. In recent years, 
depression and anxiety have also been suggested to play an important role in the activation 
of SLE, given their associations with proteinuria [39]. 
The clinical onset of SLE requires an interaction of genetic predisposition, environmental 
precipitants, immunological and hormonal factors. In such a permissive environment, 
along with proinflammatory stimuli such as T1 IFN and other cytokines, immune tolerance 
to self-Ags is lost [1]. Autoimmunity then follows driven by a complex interplay of 
defective clearance of apoptotic waste and ICs along with neutrophil extracellular traps 
(NETs), sensing of nucleic acids, disturbed T lymphocyte haemostasis, and disrupted IFN 
pathways [1].  
The identification of strong T1 IFN signature in lupus recognized the pivotal role of the 
innate immune system [20]. SLE has a wide spectrum of disease expression, with aberrant 
host innate and adaptive immune responses against self-Ags which induce the production 
of auto-Abs and the deposition of ICs in tissues leading to the activation of complement, 
accumulation of neutrophils and monocytes, and self-reactive lymphocytes. SLE-
associated auto-Abs and high serum IFN-α levels are two important heritable phenotypes 
in SLE which are thought to play a role in the disease pathogenesis. Breakdown of self-
tolerance is critical in the development of SLE. T cells are defective and their aberration in 
lupus is complex [1, 40]. 
 Regulatory T cells (Tregs) are important gatekeepers in preventing aberrant activation of 
self-reactive lymphocytes. Treg lymphocytes constitute a separate lineage of CD4+ T cells 
which maintain the immunotolerance by a direct inhibitory effect on conventional effector 
T cells (Tconv) or by secretion of immunoregulatory cytokines. Tregs are induced from 
naïve CD4+ T cells and IL-2 is critical for their differentiation and function. It is well 
known that IL-2 production by conventional Tconv is impaired in SLE. IL-2 gene is 
silenced through a transcriptional regulator, cyclic AMP response element modulator alpha, 
which is over- expressed by SLE Tconv cells. The absence of IL-2 probably favours the 
differentiation and the expansion of IFN-γ-producing Th1 cells and IL-17-producing Th17 
cells, accumulating in organs such as the skin and the kidney [41]. Tregs which suppress 
Th cells and B cells, are impaired in SLE. Furthermore, an excess of double-negative T 
lymphocytes is observed and overall, an excess of autoreactive B cells, with B cell 
lymphopenia and hyperactivation of BLyS or BAFF pathways is detected. T cells stimulate 
B cell proliferation and are necessary for the secretion of high-affinity class-switched IgG 
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Abs, in a process called T lymphocyte help. T cells in SLE provide an excessive help to B 
cells for the Ab production and these auto-Abs are strongly associated with tissue damage 
in SLE [42, Fig. 1]. 
 
Figure 1. Overview of immunological pathways leading to SLE. The development of SLE 
occurs in three interconnected phases, illustrated by coloured back grounds. Loss of adaptive 
immune tolerance (blue) leads to an increase in autoreactive B cells. Signals from self-antigens, 
TLR ligands, BAFF/APRIL and T-cell-derived cytokines promote the formation of germinal 
centres and the production of autoantibodies. Innate immune defects leading to increased 
availability of self-antigens (pink) include increased NETosis, impaired clearance of apoptotic 
debris and reduced phagocytosis. Self-antigens form ICs with autoantibodies, enabling FcRg-
mediated uptake and activation of several downstream pathways. Inflammation and tissue damage 
(green) is caused by mediators released by recruited inflammatory cells and IC-induced 
complement activation. Abs: antibodies; Ags: antigens; APRIL (CD256): a proliferation-inducing 
ligand; B: B cell; BAFF (CD257): B-cell-activating factor; BAFF-R: B-cell-activating factor 
receptor; BCMA: B-cell maturation antigen; BCR: B-cell antigen receptor; FcRg: Fc receptor-g; 
fDC: follicular dendritic cell; HLA class II: human leucocyte antigen class II; mDC:myeloid 
dendritic cell; M_: macrophage; Mo: monocyte; NET: neutrophil extracellular trap; ox-mDNA: 
oxidized mitochondrial DNA; pDC: plasmacytoid dendritic cell; Stat1: signal transducer and 
activator of transcription (a transcription factor); T: T cell; TACI (CD267): transmembrane 
activator, calcium modulator and cyclophilin ligand interactor; T-bet: a T-box transcription factor; 
Tfh: T follicular helper; TLR7/9: Toll-like receptors 7 and 9. (Zharkova2017). 
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There are other abnormalities in B and T cells including an abnormal T cell receptor 
complex, alterations on proteins that influence the T cell response to inflammation in 
various ways, such as mitogen activated protein kinase, decreased concentrations of 
blunting molecules such as Lyn (LCK/Yes-related novel tyrosine kinase, impaired 
signalling via the B cell inhibitory receptor FcgRIIB, and a faster response to a B cell 
proliferation stimulus such as proliferation-inducing ligand (APRIL) or B lymphocyte 
stimulator (BLyS) [22]. 
DCs play a key role in the production of T1 IFN and have also a role in the clearance and 
sensing of nucleic acids and ICs with known auto-Ags in lupus. The endogenous and 
external nucleic acids are a major antigenic stimulus in lupus. Auto-Abs targeting nucleic 
acid-bound Ags are one of the hallmarks of the disease. The major source of such Ags 
come from apoptosis and NETs [43]. Excess and impaired degradation of NETs are 
associated with lupus severity, lupus nephritis, anti-dsDNA Abs and complement 
consumption [44]. 
Apoptosis is pivotal in the pathogenesis of lupus. Apoptotic cells such as UV light exposed 
keratinocytes release blebs rich in auto-Ags including Ro, La, and RNP [45]. In in vivo 
photosensitivity for example, ICs with endogenous nucleic acids can activate pDCs via 
activation of TLR7 and 9 to produce conspicuous amounts of T1 IFN [46]. These particles 
are physiologically coated by molecules such as C1q and IgM to facilitate phagocytosis 
and clearance in an “immunologically silent” and anti-inflammatory environment as 
mediated by DCs [47]. 
Excessive non-cleared apoptotic waste is associated with inflammation and auto-Abs 
production. Dysregulated apoptosis and defective clearance of cellular debris increases 
auto-Ags exposure and tolerance breakdown. In SLE, apoptosis, particularly of T 
lymphocytes, is dysregulated in a Fas/Fas ligand (FasL)-dependent pathway in which FasL 
is hyperexpressed and correlates with SLE activity and auto-Abs concentrations. 
Abnormalities in the innate immune system, including that of phagocytes and complement, 
are also linked to impaired recognition and clearance of apoptotic bodies. Subsequently, 
abnormal prolonged exposure of nuclear Ags that undergo multiple alterations creates neo-
epitopes or uncovers hidden ones. The remaining apoptotic bodies then go through a 
process called secondary necrosis that leads to the release of even more nuclear material. 
The presence of auto-reactive B and T cells in SLE, responsible for the aberrant production 
of a broad and heterogeneous group of auto-Abs, particularly dsDNA and small nuclear 
RNA-binding proteins. In 2004 Sherer et al. reported that one hundred sixteen auto-Abs 
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have been described in SLE patients [48]. 
In SLE, especially in the systemic form, auto-Abs directed to nuclear (ANAs), 
cytoplasmic, and cellular membrane Ags are considered the serological hallmark. ANAs 
consist of various types of auto-Abs characterized by different antigen specificities. These 
nuclear Ags include single strand (ssDNA) and double strand (dsDNA), histone proteins, 
nucleosome (histone-DNA complex), centromere proteins, extractable nuclear Ags (ENA), 
Smith antigen (Sm), Ro, La, ribonucleoprotein (RNP), etc. ANAs are present in about 95% 
of SLE patients with an active disease. In patients with prevalent cutaneous lesions, ANAs 
have been found positive in 75% of cases [49]. 
The presence of auto-Abs in SLE was envisaged when the lupus phenomenon was 
described by Hargraves et al. in 1948 [50] and then proven when it was understood that it 
was due to neutrophil phagocytosis of cell nuclei opsonised by auto-Abs. 
 In 1957, auto-Abs against DNA were identified [51] and in 1966 Tan and Kunkel found 
auto-Abs directed to Ags different from DNA and described the anti-Sm auto-Abs [52]. 
Common auto-Abs-mediated mechanisms of damage in SLE include immune complex 
mediate damage, cell surface binding and cytotoxicity, reactivity with auto-Ags expressed 
on apoptotic or activated cell surface, penetration into living cells, and binding to cross 
reactive extracellular molecules [42]. 
Auto-Abs to dsDNA are useful for the diagnosis of SLE, to monitor the disease activity, 
and correlate with renal and central nervous involvements. Anti-dsDNA auto-Abs have 
high specificity and are universally used as a diagnostic criterion for SLE (70–98% of 
patients are positive for such Abs) [49], and for monitoring the clinical course of the 
patient. Anti-dsDNA auto-Abs, in particular of the IgG isotype, have an important 
pathogenetic role in SLE. A clear-cut relationship exists, for example, between anti-
dsDNA auto-Abs (R4A antibody) and disease activity in nephritis [53]. Moreover, anti-
dsDNA auto-Abs also contribute to the end-stage lupus nephritis by directly binding 
exposed chromatine fragments in glomerular basement membrane [54]. On the other hand, 
IgM class anti-dsDNA auto-Abs seem to have a protective role for nephropathy [55]. 
Furthermore, De Giorgio et al. demonstrated that a subset of anti-DNA auto-Abs cross-
reacts with N-methyl-D-aspartate receptors (NMDAR), and through an excitotoxic 
mechanism, could induce neuronal apoptosis. Anti-NMDAR auto-Abs are present in 40% 
of lupus patients and some reports have supported the correlation between such auto-Abs 
and the presence of neuropsychiatric lupus [56]. The anti-NMDAR auto-Abs also bind 
C1q; therefore, Franchin et al. hypothesized that this subset of anti-DNA Abs contributes to 
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lupus pathogenesis through direct targeting of C1q on glomeruli [57]. 
Anti-Sm auto-Abs are highly specific for SLE. Anti-nucleosome Abs are an excellent 
marker for SLE and good predictors of flares in quiescent lupus. Anti-Sm auto-Abs are a 
highly specific marker for SLE and Anti-Sm reactivity is not described in other diseases. 
Their sensitivity is however low. In fact, Anti-Sm Abs are detectable only in 20% of SLE 
white patients, but 30–40% in black and Asian people. 
Anti-nucleosome auto-Abs are an excellent marker for SLE and good predictors of flares in 
quiescent lupus [58]. Anti-histone  auto-Abs characterize drug-induced lupus, in about 
96% of patients with SLE induced by procainamide [59] and 100% of patients with SLE 
induced by penicillamine, isoniazid [60], and methyldopa have anti-histone auto-Abs, 
while anti-SSA/Ro and anti-SSB/La Abs are associated with neonatal lupus erythematosus 
(NLE) and photosensitivity [61]. Anti-ribosomal P (Anti-RNP) Abs play a role in 
neuropsychiatric lupus, but their association with clinical manifestations is still unclear. 
Anti-C1q Abs amplify glomerular injury, and the elevation of their titers may predict renal 
flares [62]. Anti-RNP auto-Abs are a marker of Sharp’s syndrome but can be found in SLE 
as well. Anti-proliferating cell nuclear antigen (PCNA) auto-Abs are present in 5–10% of 
SLE patients especially those with arthritis and hypocomplementemia [63]. 
Anti-phospholipid (aPL) Abs are a key feature in both Antiphospholipid syndrome (APS) 
and SLE [64]. They are found in all patients with APS and in 20–30% of patients with SLE 
[65], but only 1/3 of them develop clinical features of anti-PL syndrome [66]. Among SLE 
patients, auto-Abs including aPL Abs can be detected up to 10 years before diagnosis in 
85% of SLE patients [67]. Auto-Abs lead to the formation of ICs that directly induce B 
cells to produce more Abs and enhance the TLR/IFN1 pathway, which also stimulates B 
cells to differentiate into plasma-blasts. 
The diagnosis of SLE is made based on a combination of typical clinical manifestations 
and positive serologies. Given the wide heterogeneity of clinical manifestations, several 
sets of classification criteria have been developed over time for epidemiological and 
research purposes. 
The ACR classification criteria, first published in 1971 and subsequently revised in 1982 
and in 1997, has been the most widely used. 
In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) group published 
validated criteria that have higher sensitivity than the revised ACR criteria. They also have 
lower specificity, although not statistically significant, which might lead to the inclusion of 
more patients in clinical trials. Furthermore, the SLICC criteria showed some changes that 
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might improve their use in clinical practice. Some criteria (e.g. photosensitivity, malar rash) 
were reorganised in order to minimise overlaps, while others (e.g. neurological 
manifestations, arthritis) were redefined. Among the immunological criteria, ANA, anti-
dsDNA, anti-Sm and anti-aPL auto-Abs are now considered different criteria, so each one 
can contribute to the classification of SLE. Low complement is a new criterion. 
 Using the SLICC classification, at least four criteria from a list of clinical and 
immunological features (Table 1), including at least one clinical criterion and one 
immunological criterion, should be present for a patient to be deemed to have SLE. 
However, biopsy-proven lupus nephritis (LN) together with ANA and anti-dsDNA may 
also be sufficient. The mandatory presence of clinical and immunological features is useful 
in order to avoid inclusion of patients without clinical manifestations or without positive 
Abs [68]. 
The 2018 European League Against Rhematism (EULAR) criteria, developed for research 
only, requires an ANA of 1:80 or higher, and then eight lupus manifestations (for a score 
of 10) [69].  Direct comparison of the 3 sets of criteria using the SLICC validation cohort 
showed that they perform similarly with a sensitivity and specificity of 89% and 90% for 
the EULAR, 83% and 96% for the ACR, and 97% and 84% for the SLICC criteria, 
respectively [70].  
A systematic review and meta-analysis including 5236 patients and 1313 controls showed 
that the SLICC criteria have better sensitivity (94.6% vs. 89.6%) and similar specificity 
(95.5% vs. 98.1%) for adult SLE as compared to the 1997 ACR criteria [71]. 
SLE is highly heterogeneous clinical complex disease; it has variable presentation and an 
unpredictable course. It progresses in acute flares and periods of remission, although there 
are probably long periods of subclinical inflammatory activity. It can affect virtually every 
organ and system in the body, and during the flares more than one organ is usually 
affected. In mild forms, joints and skin are the main organs affected. In moderate forms, 
other organs are involved, but it is a severe disease, notably of the kidneys and heart, that 
can be life-threatening. Cardiac and cardiovascular system diseases are inter alia caused by 
atherosclerosis, vasculitis, and thromboembolic events. Many studies highlighted that SLE 
is associated with coronary heart disease and atherosclerosis [72-74]; an important 
prospective study has demonstrated that SLE patients have an accelerated progression of 
carotid plaque formations compared to non-lupus controls [75]. SLE patients have a 
reduced life expectancy mainly due to increased prevalence of cardiovascular diseases 
(CVD). Coronary artery disease is responsible for 30% of deaths in SLE [76]. 
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1982 revised ACR criteria  SLICC classification system 
Clinical criteria Clinical criteria 
Must meet 4 of 11 criteria  
-Malar rash 
-Discoid rash  
-Photosensitivity 
- Oral rash  
-Arthritis  
-Serositis: a) pleuritis; b) pericarditis 
-Renal disorder: a) proteinuria>0.5g/24h or 3+, 
persistently; b) cellular cast 
-Neurological disorder: a) seizures; b) psychosis 
(excluding other causes, eg drugs) 
-Haematological disorder: a) haemolytic anaemia 
with reticulocytosis; b) leukopenia or <4000/mm³ 
on two or more occasions); d) thrombocytopenia 
(<100,000/mm³) 
-Immunological disorders: a) positive lupus 
erythematous cell; b) raised anti-native DNA 
antibody binding; c) anti Sm antibody; d) false-
positive serological test for syphilis, present for at 
least six months 
Must meet 4 criteria (including 1 clinical and 
immunological) 
-Acute cutaneous lupus (1 or more of the 
following): a) malar rash; b) bullous lupus; c) 
maculopapular rash; d) photosensitive rash 
-Chronic cutaneous lupus (1 or more of the 
following): a) classic discoid (localised vs. 
generalised); b) hypertrophic lupus; c) lupus 
panniculitis; d) mucosal lupus; e) lupus 
erythematous tumidus; f) chilblanis lupus; g) 
discoid lupus/lichen planus overlap 
-Oral or nasal ulcers  
-Non scaring alopecia  
-Synovitis OR tendonitis: 2 or more joints;  
morning stiffness 
-Serositis: a) pleural; b) pericardial  
-Renal: a) urine protein-to-creatinine ratio with 
more than 500mg protein/24 h; b) red blood cells 
casts  
-Neurological disorders (1 or more of the 
following): a) seizures; b) psychosis; c) 
mononeuritis multiplex; d) myelitis; e) neuropathy; 
f) acute confusional state 
-Haematological disorder: a) haemolytic anaemia; 
b) leukopenia (<4000/mm³at least once), c) 
lymphopenia (<1000/mm³ at least once); d) 
thrombocytopenia (<100,000/mm³) 
 
Immunological criteria Immunological criteria 
Abnormal titer of ANA a) ANA above reference range; b) anti-
dsDNA above reference range; c) anti-Sm; 
d) antiphospholipdantbody positivity; e) 
low complement; f) direct coombs (in 
absence of haemolytic anaemia) 
 Table 1. SLE classification criteria of ACR and SLICC (Santos, 2019). 
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Patients with SLE are at a higher risk of developing accelerated atherosclerosis. Multiple 
studies suggest that these patients have between a 9-fold and 50-fold increase in risk of 
developing CVD compared with non-SLE patients. These increases result from a 
combination of traditional risk factors, and dysfunctional immune and inflammatory 
mechanisms [77]. The data suggests that SLE is per se a strong independent risk factor for 
the development of CVE, comparable even to type I diabetes mellitus (DM) [78]. The 
relative risk of myocardial infarction is five to eight times greater than that of the general 
population, and more than 1/3 of SLE patients exhibit evidence of carotid plaques or 
coronary artery calcifications. Premature atherosclerosis has been recognized as a major 
comorbidity condition in SLE as evidenced by the increased carotid intima-media 
thickness (CIMT) score and prevalence of carotid plaques in several systematic reviews 
and meta-analyses [79]. 
 
Accelerated atherosclerosis in SLE 
 
Accelerated atherosclerosis in SLE has been initially demonstrated in 1975 by Bulkley et 
al. [80] in a necroscopic study, that was further confirmed by Urowitz et al. [81]; they first 
reported an increased risk of CVD in SLE patients. This study outlined a bimodal curve of 
mortality for SLE, where early deaths (<1 year after diagnosis) were attributable to kidney 
disease and infections, while later deaths were associated with CVD [81]. 
Women with SLE in the 35-44 year old age group have an estimated 50-fold increased risk 
of myocardial infarction compared with age and sex-matched controls, as well as an 
increased incidence of subclinical atherosclerosis [82]. 
Atherosclerosis is a multifactorial disease for which a number of pathogenic mechanisms 
have been proposed. In addition to classical risk factors, in the last two decades the 
attention has focused on the inflammatory processes [83]. Increased atherosclerosis in SLE 
patients is thought to result from a combination of traditional risk factors together with the 
inflammatory burden and the immune dysregulation characterizing SLE (Fig. 2). Certain 
traditional CV risk factors have been found to be increased in patients with SLE, especially 
hypertension and a “lupus pattern” dyslipidaemia, SLE patients exhibit a proatherogenic 
lipid profile characterized by high levels of very low-density lipoprotein (VLDL) 
cholesterol, triglycerides, low levels of high-density lipoprotein (HDL) and high or 
unchanged low-density lipoprotein (LDL). Other factors such as smoking, DM, older age 
and hyperhomocysteinemia have all been linked to subclinical atherosclerosis and/or CV 
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events in these patients [84]. MTHFR 677 TT polymorphisms is the main genetic 
determinant for hyperhomocysteinemia and it has been shown to be an independent 
predictor for lupus related subclinical atherosclerosis [85]. 
 
 
 
Figure 2. Mechanism of increased risk of cardiovascular disease in SLE. A number of 
pathogenic mechanisms contribute to the accelerated atherosclerosis and vascular injury in SLE. 
High-density lipoprotein (HDL), which protects low-density lipoproteins (LDLs) from oxidation by 
reactive oxygen species (ROS), becomes proinflammatory (piHDL). Ox-LDL activates endothelial 
cells (ECs) to produce proinflammatory cytokines, recruiting monocytes/macrophages to the 
lesions. Ox-LDL promotes differentiation of monocytes/macrophages into foam cells. 
Plasmacytoid dendritic cells (pDCs) and low-density granulocytes (LDGs) secrete type I 
interferons (IFNs), which impairs maturation of smooth muscle cell (SMC), promotes dysfunction 
of endothelial progenitor cell (EPC)/circulating angiogenic cell (CAC) differentiation into mature 
ECs, and induces platelet activation. Neutrophil extracellular traps (NETs) induce endothelial 
dysfunction and EC death and prime macrophages for interleukin (IL)-1β production. B1a B cells 
preferentially class switch to pathogenic IgG-producing B1a B cells. B2 B cells produce 
autoantibodies, such as anti–β2-GPI. Anti–β2-GPI forms complexes with ox-LDL/β2-GPI, further 
promoting foam cell formation and proinflammatory cytokine and chemokine expression. aβ2-GPI, 
Anti–β2-glycoprotein I antibodies; MCP-1, monocyte chemotactic protein-1; MMP, matrix 
metalloproteinase; ox-LDL, oxidized LDL; TNF, tumor necrosis factor. (Yudong Liu, 2019). 
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Atherosclerosis is a chronic inflammatory disease of the arterial wall, in which 
macrophages, T cells, and vascular smooth muscle cells (VSMCs) are important cellular 
components of the atherosclerotic lesion. Innate and adaptive immunoinflammatory 
mechanisms are involved in the formation of the early fatty streak, as reported, when the 
endothelium is activated and expresses chemokines and adhesion molecules, leading to 
monocyte/T lymphocyte recruitment and infiltration into the sub-endothelium. It also acts 
at the onset of adverse clinical vascular events when activated cells within the plaque 
secrete matrix metalloproteases (MMPs) degrading extracellular matrix proteins and 
weakening the fibrous cap, with consequent plaque rupture and thrombus formation [86]. 
Within the T cell population infiltrating the plaque, most cells are activated CD4+ Th1 cells 
and Th17 cells expressing HLA-DR and the IL-2 receptor (IL-2R) [87]. DCs and B cells 
are also present in the plaque and in the adventitia and they play important roles in the 
disease process. 
There are evidences indicating that autoimmunity can be detected within the 
atherosclerotic lesions [88]. Accordingly, self-phospholipids, such as oxidized low-density 
lipoproteins (oxLDL) and human heat shock proteins (hHSPs), drive T cell inflammation 
in atherosclerotic patients [89]. 
An early step in atherogenesis is the endothelial dysfunction, resulting in increased 
permeability to circulating LDL and recruitment of leukocytes. In SLE the integrity and 
repair mechanisms of endothelial cells (ECs) may be affected through direct binding of 
auto-Abs to ECs or deposition of circulating ICs [90]. The consequent endothelial damage 
promotes atherogenesis, which has been divided into three stages. The inflammatory 
process triggers the first stage, which consists in the expression of surface adhesion 
molecules. At the second stage, the adherent leukocytes migrate across the intima layer and 
penetrate the media layer [91]. The transmigration process is mediated by monocyte 
chemotactic protein-1 (MCP-1); in humans, elevated circulating levels of MCP-1 correlate 
to increased CIMT [92]. Tumor necrosis factor (TNF)-α, IL-1, and oxLDL have an 
important role in the first two stages of atherosclerosis, as they up-regulate adhesion 
molecules and MCP-1 [93]. Conversely, transforming growth factor-beta (TGF-β) 
suppresses smooth muscle (SMCs) and ECs proliferation. Decreased levels of TGF-β was 
associated with premature atherosclerosis in lupus-prone mice [94], supporting the 
hypothesis that the down-regulation of this cytokine can lead to arterial wall dysfunction 
with subsequent atherosclerosis development. Finally, in the last stage, macrophages foam 
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cells formation takes place along with replication of SMCs leading to plaque propagation 
and rupture [91]. This complex stage starts with the entrapment of LDL in the sub-
endothelial space where they are exposed to reactive oxygen species (ROS) produced by 
nearby arterial wall cells and then converted to pro-inflammatory oxLDL. The exposure of 
ECs to oxLDL results in the production of more MCP-1, macrophage colony-stimulating 
factor (M-CSF) and GRO, which further contribute to monocyte binding, chemotaxis, and 
differentiation into macrophages [95]. In addition, when oxLDL are being exposed to 
macrophages, the inhibition of the phagocytosis of apoptotic cells takes place and the 
expression of the scavenger receptor CD36 is promoted, further increasing oxLDL 
phagocytosis [96], leading to foam cells formation around which atherosclerotic lesions are 
built. Elevated levels of circulating oxLDL have also been described in SLE patients, 
especially in those with a history of CVD, and in the general population affected by 
coronary heart disease. Monocytes and T cells infiltrate the margin of the plaque formed 
by foam cells and SMCs which encroach on the lumen of the vessel and ultimately lead to 
fibrosis, that renders the plaques fragile. The occlusion that results in MI can occur when 
one of these plaques ruptures takes place, or when platelets aggregate in the narrowed area 
of the artery. 
In SLE, LDL display both greater susceptibility to oxidation and ability to increase 
oxidative stress levels [97]. Furthermore, a dysfunctional form of HDL (piHDL) that arises 
under inflammatory conditions, present in SLE patients, seems to lack the regular anti-
inflammatory and antioxidant properties of HDL. As a result, it fails to efficiently 
participate in cholesterol efflux and enables the oxidation of LDL [98]. 
oxLDL, is highly immunogenic; unlike native LDL, they can also form complexes with 
β2-GPI, which are significantly elevated in SLE with or without APS [99]. The presence of 
IgG anti β2GPI increases oxLDL uptake by macrophages [100]. Both, elevated levels of 
circulating oxLDL and of auto-Abs against oxLDL, are more common in SLE patients 
with CVD, than in patients without CVD [101]. The increased levels of auto-Abs against 
epitopes of oxLDL has also been associated with maximum IMT scores and progression of 
atherosclerosis [102]. Once oxLDL become immunogenic promoting an immune humoral 
response against oxLDL resulting in B cell activation, Ab production and formation of ICs, 
all of which participate in the atherosclerotic process, in complex and distinct ways [103]. 
Nevertheless, the heterogeneity among Ig subclasses and the epitopes specificity and 
affinity might explain the diverse properties of oxLDL auto-Abs. In fact, only IgG are 
thought to promote atherogenesis, while IgM seem to protect atherosclerosis prone mice 
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from inflammatory oxidized moieties [104]. 
TNF-α also plays a role at the last stage of the disease as it suppresses lipoprotein lipase 
synthesis, thus inhibiting the metabolism of triglycerides and VLDL [105]. The protective 
mechanism of efflux of cellular cholesterol is thought to be impaired in SLE, as the 
responsible enzyme for this process, cholesterol 27-hydroxylase, has been shown to be 
decreased in cultured human monocytes and aortic ECs of SLE patients [106]. 
The relationship between lupus and atherosclerosis came with the identification of 
NETosis as a key pathophysiological element. NETosisis a type of cell death pathway that 
results from externalization of chromatin fibres decorated with granule-derived 
antimicrobial peptides and is one of the defense mechanisms of neutrophils against 
pathogens. NETs contain many proinflammatory antimicrobial molecules that induce ECs 
death and vascular dysfunction. 
In SLE, there is a deficient clearing of these NETs, which increases the production and 
release of T1 IFN and further enhancing NETosis [107]. Impaired degradation of NETs is 
presumably due to the presence of Abs against deoxyribonuclease (DNase) I, the main 
degrader of NETs, or due to the presence of anti-NET Abs that protect NETs from 
degradation [108]. NETs also lead to increased inflammasome activation, by increasing the 
synthesis of activated IL-1β and IL-18, which induce a positive loop in NETs formation 
[109]. 
Low-density granulocytes (LDGs), a subtype of neutrophils prevalent in SLE, are 
particular prone to predispose to NETosis. LDG NETs are deleterious for the endothelium 
thus contributing to accelerated atherosclerosis in SLE, as they synthesize increased levels 
of pro-inflammatory cytokines, mainly IFN-α and disrupt the differentiation of endothelial 
progenitor cells (EPCs) to mature ECs. LDGs also display significant increases in 
mitochondrial ROS production. The oxidation of mitochondrial DNA (mtDNA), mediated 
by ROS, allows the migration of mtDNA to the cellular surface, thereby triggering potent 
pro-inflammatory and interferogenic responses [110]. Vitamin D regulates several 
important immune functions and its deficiency has been linked to premature 
atherosclerosis [111]. Vitamin D deficiency is common in patients with SLE and is 
associated with increased disease activity. Lower vitamin D is associated with increased 
aortic stiffness in patients with SLE. Increased disease activity may mediate the association 
between vitamin D deficiency and vascular stiffness [112]. 
T cells can be found in atherosclerotic plaques both in humans and mice, making up 
approximately 10% of the cells in the lesion [113]. Th cells form a main branch of the 
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inflammatory response in the pathogenesis of autoimmune diseases. T cells have a 
significant role in SLE pathogenesis. Overall, SLE T cells have been shown to be 
hyperactive, with a reduced threshold of activation [114]. Upon activation, these cells 
secrete inflammatory cytokines such as IFN-γ and IL-17. In addition, SLE T cells exhibit 
increased survival and are resistant to apoptosis [115]. These properties of SLE T cells 
contribute to disease pathogenesis and result in the activation of DCs and B cells [116]. 
There are different effects of each of T cells on atherosclerosis. The CD4+ T cells can be 
classified into Th1, Th2 and Th17, and Treg cells based on the distinct cytokine repertoire. 
Each subset plays specific roles in atherosclerosis. The Ags (oxLDL, HSPs, phosphoryl 
choline, apoptotic bodies) may induce Th1, Th2, or both Th1 and Th2 pathogenic 
responses. The imbalance of Th subsets, including Th1, Th2, and Th17, is suggested to 
contribute to the development of SLE. Schulte et al. demonstrated that mice skewed more 
towards a Th1 phenotype dislpay increased atherosclerosis, while a bias towards a Th2 
phenotype resulted in lower atherosclerosis [117]. 
The majority of T cells in atherosclerotic lesions, CD4+ T cells with a Th1 phenotype are 
the primary T cell subset. The CD40/CD40L pathway is critical for Th1 differentiation. 
Th1cells are the main producers of IFN-γ, upon activation by plaque Ags. IFN-γ secretion 
leads to a further skewed Th1 response as it polarizes T cells toward the Th1 phenotype. 
The Th1 bias promotes atherosclerosis in both humans and mice [118]. 
A plethora of cytokines, including IFNs, has been shown to be important atherogenic 
regulators. Already in 1989, Hansson et al. [119] observed IFN-γ and IFN-γ–producing T 
cells to be abundant in human atherosclerotic plaques. IFNs are generally pro-
atherosclerotic and have a complex role in different stages of atherosclerosis. 
The pro-inflammatory cytokine IFN-γ is secreted by Th1. IFN-γ plays a role in cells 
recruitment to the atherosclerotic lesion. IFN-γ can subsequently activate macrophages 
resulting in the secretion of pro-inflammatory mediators such as IL-12 and IL-18. IFNs are 
also important regulators of macrophage migration toward the atherosclerotic plaque and 
under the influence of IFN-γ. Antigen presentation is enhanced by up-regulating both 
major histocompatibility complex class (MHC) I and class II molecules expression on 
activated macrophages and the induction of MHC II expression on mature DCs. This 
results in a second wave of T cell activation. IFN-γ is known to induce the expression of 
ECs adhesion molecules crucial for leukocyte recruitment to the plaque. Their expression 
can be further intensified by a cross talk between IFN-γ and lipopolysaccharide signalling 
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in atherosclerosis. IFN-γ also induces the expression of several chemokines, such as 
CXCL9, CXCL10, and CCL2, thereby further promoting cell recruitment toward the 
atherosclerotic plaque. Taken together these evidences demonstrate that IFN-γ can promote 
leukocyte recruitment to atherosclerotic lesions and promotes foam cell formation by 
increasing the expression of the scavenger receptor for phosphatidylserine and oxLDL. 
Lupus T cells synthesize significantly larger amounts of IFN-γ [120], one of the most 
important over-expressed cytokine in SLE, which up-regulates several pro-atherogenic 
processes such as the production of lipid mediators, platelet activating factors and 
eicosanoids, antigen presentation, and synthesis of TNF-α and IL-1 [121].  
IFN-γ also inhibits collagen I and III production in VSMCs, destabilizing the plaque by 
reducing extracellular matrix production and inhibiting SMCs and ECs thereby increasing 
plaque vulnerability [122,123]. T1 IFN cytokine family is represented primarily by IFN-α 
and IFN-β, prototypical Th1 cytokine promotes, mainly produced by pDCs have also been 
found in atherosclerotic plaques. The activation of TLR7 and 9 is responsible for the up-
regulation of IFN-α expression [124], which has been established as an atherogenic 
cytokine, and high levels of IFN-α production are induced by TLR 9-pDCs interaction. In 
subjects with SLE, pDCs induce the expansion of CXCR3+ CD4+ T cells and their 
migration from the bloodstream into the arterial wall, in which they may play pathogenic 
roles [125]. There is a chronic exposure to T1 IFN in SLE, which can promote and sustain 
chronic endothelial dysfunction, eventually leading to atherosclerosis. T1 IFNs may play a 
critical role in lupus CVD pathogenesis and the pro-atherogenic effect of IFN-α plays an 
important role in the development of premature atherosclerosis of SLE patient. The effect 
of IFN-α is supported by mice experiments, where a correlation among the depletion, 
dysfunction of EPCs and excessive T1 IFN levels was found [126]. An imbalance between 
ECs damage and repair develops as a result of alterations in EPCs and myelomonocyte 
circulating angiogenic cells (CACs) which are mediated by IFN-α. Furthermore, IFN-α is 
also responsible for plaque instability, as it inhibits the growth of SMCs, ECs, and the 
production of collagen trough mechanisms that are not fully understood. IFN-α also 
promotes atherosclerosis by various mechanisms by affecting adhesion and migration of 
leucocytes to plaques and by promoting plaque rupture [123]. 
Apoptosis is a common phenomenon in macrophage-rich areas of atherosclerotic lesions. 
Defective clearance of apoptotic cells, or efferocytosis, results in the formation of an 
inflammatory necrotic core, which makes plaques prone to rupture. Both T1 IFN and T2 
IFN are implicated in the regulation of apoptosis. 
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Another T cell subset with a potential role in SLE-accelerated atherosclerosis is the Th17 
subset. Th17 cells constitute a distinct lineage of Th cells characterized by the expression 
of transcription factor RAR-related orphan nuclear receptor (ROR) γt and by the 
production of pro-inflammatory cytokines [127]. IL-17 is known to play a role in both 
lupus and atherosclerosis. 
Other Th17-related cytokines include interleukin IL-21, IL-22 and IL-6 as well as soluble 
CD40 ligand (sCD40L), which can be produced by Th17 cells and is involved in the 
development and differentiation of Th17 cells. Studies reported that serum levels of IL-21, 
IL-17A, IL-6, and sCD40L of SLE patients are all higher than the respective serum levels 
in healthy controls [128]. The levels of IL-17A are significantly increased and correlate 
with disease activity [129], tending to be higher in individuals with active nephritis [41]. 
There are complex interactions between Th17-related cytokines, it is reported that IL-21 
can induce expansion of IL-17A-producing Th17 cells through initiating an alternative 
pathway [130]. However, other studies showed that IL-21 suppresses the production of IL- 
17 [131]. IL-17A can be produced by neutrophils when stimulated by IL-6 [132]. 
Moreover, IL-6 can enhance the cellular expression of IL-21R, IL-21, and activate STAT3, 
a main regulator of IL-21 and IL-6 signaling [133]. IL-6 is a key cytokine that inhibits 
Foxp3 expression during Treg cell differentiation [134]; increased production of IL-6 has 
been documented in SLE patients [134,135]. Thus, oxidative stress, which induces 
increased production of IL-6, may be the primary reason for the decrease in Treg cells in 
SLE patients. IL-6 is a potent cytokine produced by innate and adaptive cells. It stimulates 
B cell growth and B and T cell differentiation. The pro-atherogenic functions of CD40 
ligation include augmented expression of MMPs, procoagulant tissue factor (TF), 
chemokines, and cytokines [136]. Th17 cells are present in atherosclerotic plaques of both 
mice and humans [137,138]. IL-17A also promotes plaque development in animal models 
of atherosclerosis [139,140]. The role of IL-17A in atherosclerosis development in SLE 
remains unknown, but LDLR knock-out mice receiving CD4+T cells from lupus-prone 
mice develop accelerated atherosclerosis caused by an imbalance between IL-17 
production and Tregs function. As the development of Th17 cells shares many similarities 
with Tregs' one and they are reciprocally regulated, the imbalance between these two cell 
subsets is a major immune deregulation occurring in SLE [141]. It has been suggested that 
a Tregs/Th17 imbalance could lead to a putative escape of autoreactive Th17 cells from 
Tregs control, thus facilitating autoimmunization. sCD40L, which is shed from activated 
platelets or T cells, is a marker of autoimmune diseases and platelet activation [142]. The 
66  
plasma concentration of sCD40L is increased in SLE patients, correlates with T cell 
activation, Th17/Treg cells balance and with the co-stimulatory pathways of humoral 
immunity via persistent chronic activation of B cells [143]. 
There is another subset of Th17 cells, named Th17/Th1 cells, that also secrete IFN-. 
Interestingly, Th17/Th1 and Th1 cells appeared more pathogenic than Th17 cells in an 
experimental mouse model. The ratio of Th17/Th1 appears to be dysregulated in SLE 
patients, with an increase in Th17 in SLE [144]. In addition, the ratio of Tregs/Th17 is 
reduced in SLE patients [145]. Given their potentially pathogenic role in atherosclerosis, 
the fact that Th17 cells are increased in SLE and that Tregs are reduced suggests that the 
dysregulation of these cell types may be a factor contributing to accelerated atherosclerosis 
in SLE. The significant activation of Th1 and Th17/Th1 cells in conjunction with a reduced 
Tregs population was observed in patients with ACS, suggesting a potential role of Th1, 
Th17/Th1 and Treg cells imbalance in the development of atherosclerotic plaque instability 
[146]. 
IL-21 can influence the immune response in many ways. This cytokine can be produced 
by follicular helper T (Tfh) cells, Th17 cells, or natural killer (NK) cells. IL-21 is an 
important pleiotropic cytokine, promotes Th17 immune responses acting as a key 
modulator of development, expansion, and differentiation of lymphocytes. It can also 
modulate the function of DCs, plasma cells, and NK cells, and provide instructional cues 
for maturation of B cells and germinal center formation [147]. IL-21 has an association 
with the increasing level of auto-Abs of IgG type, and the intracellular expression of 
granzyme B in B cells, leading to immune injury and apoptosis in SLE cases [148]. The 
genome-wide association studies on the IL-21 gene identified the association between 
polymorphisms in IL-21 gene and susceptibility to autoimmune diseases such as SLE, 
RA, and multiple sclerosis [149]. The Genetic studies that have accumulated over the past 
10 years have supported that the IL-21 gene, located on chromosome 4q26–q27, has a role 
in the pathogenesis of SLE [150]. 
The role of B cells in lupus pathogenesis is more complex. In autoimmunity, B cells are 
hyperactivated and can produce pathogenic auto-Abs against nuclear elements. In 
addition to auto-Ab production, SLE B cell dysregulation can lead to T cell activation, 
DCs recruitment, induction of Th1 and Th17 cells and inhibition of Tregs, solidifying B 
cells as a major player in SLE pathogenesis [151]. Abs are produced by plasma cells, that 
represent the end point of B cell differentiation. There are two pathways for B cell 
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activation and antibody production: A T cell independent (TI) and T cell dependent (TD) 
one. Most studies indicate that TD antibody production is the main culprit [152]. In SLE, 
T cells display abnormal phenotypes, an altered activation threshold, and triggering of 
signalling pathways that lead to an increased activation and expression of co-stimulatory 
molecules such as CD40/CD40L [136]. T cell expression of CD40L is important in B cell 
differentiation, proliferation, Ig class switching, and antibody production via CD40 
interactions on the B cell [143]. Increased CD40L/CD40 interactions lead to enhanced B 
cell activity and increased production of disease-promoting auto-Abs [153]. CD40L 
signalling is also important for atherosclerosis development, and inhibition of 
CD40L/CD40 interactions results in a more stable plaque phenotype. B cell 
subpopulations and distinct Abs have complex and opposing effects on atherosclerosis. B 
cells mainly contribute to spontaneous or TI antibody production of IgM or IgA class. B1 
cells seem to bear an atheroprotective role through IgM antibody production which 
promotes reduction in necrotic core in atherosclerotic lesions. B2 cells are considered 
proatherogenic and appear to worsen atherosclerosis through the production of pathogenic 
IgG Abs against oxLDL epitopes and the promotion of an atherogenic cytokine profile 
[104]. SLE presents a suitable environment for LDL oxidation and creation of 
immunogenic oxLDL. This phenomenon coupled with aberrant B cell function in SLE 
may promote immune reaction skewed towards more prominent B2 cell and/or irregular 
B1 cell activation, as evidenced by the relative shortage of protective Abs in lupus 
patients resulting in an accelerated form of atherosclerosis development. 
Accelerated atherosclerosis in SLE may be also related with the presence of aPL Abs, 
known to increase the risk of thrombosis in SLE through several mechanisms. aPL Abs 
interact with ECs and monocytes inducing a pro-inflammatory and pro-coagulant 
phenotype [154] and activating the complement cascade, that generates C5a which in turn 
activates neutrophils and the expression of TF responsible for the initiating of the 
extrinsic coagulation cascade [155]. Specific auto-Abs against phospholipids also induce 
the expression of adhesion molecules, such as ICAM-1, VCAM-1, and E-selectin [156]. 
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Antiphospholipid Syndrome 
 
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by 
vascular thrombosis and/or pregnancy morbidity associated with the persistent presence 
of aPL Abs, which are found in all patients with APS and in 20–30% of patients with SLE 
[65], but only 1/3 of them develop APS clinical features, namely, venous thrombosis, 
arterial thrombosis, recurrent pregnancy loss, thrombocytopenia and haemolytic anaemia, 
livedo reticularis, and skin ulcers [157]. 
 Among SLE patients with a positive lupus anticoagulant (LA), 50% will develop a 
venous thrombosis over a period of 20 years [158]. In 85% of SLE patients, auto-Abs 
including aPL ones can be detected up to 10 years before diagnosis in [159]. 
APS is considered a rare disease, with an estimated incidence of five cases per 100,000 
people per year, that affects young adults of reproductive age, that adds significant 
morbidity to the affected individuals. In addition to physical sequelae, caused by 
thrombotic events, there is still considerable emotional repercussion from recurrent 
gestational losses. 
aPL Abs is the most common cause of acquired hypercoagulability and were associated 
with accelerated atherosclerosis to explain cardiovascular manifestations of the syndrome. 
Although APS and SLE differ in their clinical manifestations, there are significant overlaps 
in individual clinical features. 
The syndrome is classified into primary (PAPS) when occurring in patient without known 
autoimmune disease or secondary (SAPS) associated with autoimmune diseases, 
particularly with SLE (SLE/APS). 
The classification criteria for APS were developed in 1999 in Sapporo, and subsequently 
revised in 2006 at an international congress held in Sydney. At present, they comprise the 
requirement of at least one clinical criterion (thrombotic event or gestational morbidity) 
and at least one laboratory criterion (confirmed positive aPL Abs at two or more separate 
time points with a 12-week minimum interval), the laboratory criteria include three aPL 
Abs assays, one based on coagulation tests to reveal the presence of LA and two solid 
phase assays to detect IgG/IgM Abs targeting cardiolipin (CL)/β2GPI complexes or β2GPI 
alone (Table 2). 
Two positive Ab measurements, separated by a minimum interval of 12 weeks, should be 
obtained to rule out the possibility of a transient positivity of aPL Abs induced by 
infections or drugs [160].  
69  
 
Clinical criteria 
Vascular thrombosis  One or more episodes of arterial, venous or small vessel 
thrombosis in any tissue or organ (confirmed by objective 
validated criteria (imaging study or histopathology) 
Pregnancy complication  - One or more unexplained deaths of morphologically 
normal fetus≥10th gestational week 
-One or more premature birth (≤34th gestational week) of 
a morphologically neonate because of eclampsia, severe 
pre-eclampsia or placental insufficiency 
-Three or more unexplained consecutive spontaneous 
abortions ≤9th gestational week (maternal anatomic and 
hormonal abnormalities and chromosomal abnormalities 
excluded) 
 
Laboratory criteria  
Lupus anticoagulant present in plasma   Detected according to the guidelines of the international 
society of thrombosis and haemostasis (scientific 
subcommittee on lupus anticoagulant/phospholipid-
dependent antibodies) 
IgG and/or IgM anti-cardiolipin 
antibodies in serum or plasma  
At medium/high titer (≥40 GPL or MPL or ≥99th 
percentile) measured by standard ELISA 
IgG and/ or IgM anti-β glycoprotein I 
antibodies in serum or plasma   
Titer ≥99th percentile measured by standard ELISA, 
according to recommended procedures 
Table 2.  Revised classification criteria for APS [Pavord, 2018]  
 
 
According to the revised classification criteria, APS patients should be divided into four 
categories: category I includes patients with more than one positive test in any 
combination, while patients with a single positive test should be classified in category II 
(IIa if LA-positive, IIb if positive for Abs against CL (aCL), IIc if positive for anti-β2GPI 
Abs) [160]. 
Subjects positive for LA, high titers of aCL, and anti-β2GPI Abs (above the 99ᵗʰ percentile) 
defined as “triple positives”, more than any other aPL Abs profile, have high risks for 
thrombosis and pregnancy morbidity. The risk of recurrent thrombosis in triple-positive 
patients was around 30% over a 6-year follow-up period. Triple-positive aPL Abs patients 
usually have high titers of Abs to the major β2GPI epitope on domain I [161]. Thus, anti-
domain I β2GPI auto-Abs, which frequently present in triple aPL-positive patients, confer 
LA activity, associate with the highest risk of thrombosis, predispose to both thrombosis 
and pregnancy loss [162]. 
The presence of these Abs is essential for the diagnosis and likely to play a pathogenic role 
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in various disease manifestations. The study of aPL Abs began in 1906 when Wasserman 
introduced his serological test for syphilis [163]. In 1941, the active component was found 
to be a phospholipid, which was called CL [164]. After the 1950s, it became clear that 
people with positive Wasserman-test did not necessarily have syphilis but that they may 
have had an autoimmune disorder instead, including SLE [165]. LA is the most specific 
test for the diagnosis of APS and should be performed according to the International 
Society for Thrombosis and Haemostasis; these are functional investigations and comprise 
three stages. aCL Abs is the most sensitive test for APS diagnosis. It is performed by a 
standardized enzyme immunoassay (ELISA) technique containing a source of β2GPI. 
Internationally approved positive controls are used so that this test has less variability and 
meets international standards. This test is not influenced by warfarin and heparins: aCL 
titers are divided into low (< 40 GPL or MPL), moderate (40 to 80 GPL or MPL) or high 
(> 80 GPL or MPL). Anti-β2GPI Abs are also used and detected by ELISA, and have 
recently been included in the classification criteria. There is still no standardization for this 
methodology [166]. 
aPL Abs recognize a number of anionic negatively charged phospholipids, including CL, 
LA, phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), and 
phosphatidic acid (PA). Neutrally charged auto-antigen targets include phosphatidyl 
ethanolamine, phosphatidyl choline, platelet activating factor and sphingomyelin. These 
Abs are usually detected with radioimmunoassay and ELISA. CL remains the most 
commonly used antigen for detecting aPL Abs by ELISA. aPL Abs bind to phospholipids 
and plasma or membrane proteins expressed in various cells (platelets, ECs, monocytes, 
fibroblasts and trophoblasts), producing a prothrombotic state. Many pathogenic Abs in 
APS do not target phospholipids themselves, but rather phospholipid-binding protein 
cofactors. In APS, the auto-Abs primarily recognize phospholipid-binding proteins, such as 
β2GPI and prothrombin. aPL Abs play a major pathogenic role in inducing clinical 
manifestations; however, there is growing evidence that inflammatory stimuli are pivotal 
for triggering thrombosis, while tissue distribution of β2GPI the major antigenic target as 
well as its post-transcriptional modifications or the fine epitope specificity of anti-β2GPI 
Abs may influence the type of clinical events or even their occurrence. Both APS and SLE 
are characterized by the production of high levels of IgG class-switched auto-Abs, 
consistent with a Th cell response. The primary target in both APS and SLE is β2GPI.The 
anti-β2GPI Abs are the most thrombogenic and may exert a pathogenetic potential either as 
a strong procoagulant factor in the cerebral circulation or by directly interacting with 
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neuronal tissue [167]. 
The mechanistic schema is that anti-β2GPI Abs potentiate thrombosis by engaging β2GPI 
protein that has been recruited to cell surfaces and thereby promoting cell activation. There 
are specific roles suggested for cell surface proteins such as annexin A2, apolipoprotein E 
receptor 2 (ApoER2), TLR2 and TLR4. 
ApoER2 (also known as LDL receptor-related protein 8) is a receptor for β2GPI (and 
consequently β2GPI-dependent aPL Abs) on monocytes, ECs, and platelets. Indeed, in a 
2011 study, Ramesh and colleagues demonstrated that ApoER2−/− mice are relatively 
resistant to thrombosis when confronted with aPL. More recently, it has been revealed that 
ApoER2 may play an important role in obstetric APS. Specifically, Ulrich and colleagues 
demonstrated enhanced placental trophoblast cell proliferation and migration in vitro when 
aPL Abs engage β2GPI/ApoER2 complexes on the trophoblast cell surface. Extending 
these studies to an in vivo model of aPL Abs-mediated pregnancy loss, they demonstrated 
protection in ApoER2−/− mice [168]. In another recent study, Mineo and colleagues 
developed a monoclonal Ab against β2GPI that prevents pathogenic aPL Abs binding, 
thereby protecting against aPL Abs-mediated cell activation. This Ab attenuated the 
association of β2GPI with ApoER2, thereby normalizing endothelial and trophoblast cell 
function in vitro, as well as preventing thrombosis and fetal loss in vivo [169]. Although 
further study is clearly needed, the intersection of aPL Abs, β2GPI, and ApoER2 warrants 
further investigation as a potential therapeutic target inpatients. 
Among all SLE patients, approximately 40% of the aPL Abs-positive patients develop 
arterial and/or venous thrombosis, in comparison with 10%-20% of aPL Abs-negative 
patients (p<0.001) [170]. aPL Abs increase the risk of vascular events and death in SLE 
[171], but their role in the development of atherosclerosis in humans remains controversial. 
aPL Abs cross-react with Abs against oxLDL and may enhance its uptake by macrophages, 
which represents the initial step of atherosclerotic plaque formation. aPL Abs can also 
cross-react with HDL-complex (HDL-C) and apolipoprotein A-I (Apo A-I), a major 
constituent of the HDL-C, possibly reducing the antiatherogenic effects of HDL. Multiple 
molecules, essential in the haemostatic system, and acting as key players in thrombosis and 
atherosclerosis development, are altered in APS immune and vascular cells by the effect of 
aPL Abs, including TF, the vascular endothelial growth factor (VEGF) VEGF/Flt1 axis, 
several TLRs, annexins, protein disulfide isomerase. aPL Abs are a clinically important 
acquired risk factor for thrombosis and pregnancy loss and are thought to have a direct 
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prothrombotic effect in vivo. Data suggest that a major mechanism by which aPL Abs 
contribute to thrombophilia is the up regulation of TF on blood cells and vascular 
endothelium. TF is the physiological trigger of normal blood coagulation and thrombosis in 
many hypercoagulable conditions. TF was firstly described by Cuadrado et al. to be 
significantly elevated in monocytes from APS patients with a previous history of 
thrombosis and related to the presence of high tire of aPL Abs [172]. aPL Abs induce TF 
expression in monocytes in APS patients by activating simultaneously and independently, 
the phosphorylation of MEK1/ERK proteins, and the p38 MAP kinase-dependent nuclear 
translocation and activation of NF-kappaB/Rel proteins, with up-regulation of IL-6, IL-8 
and induced nitric oxide synthase  (iNOS). TF signalling activities are mainly mediated by 
the protease activators receptors (PARs), major mediators of thrombosis and haemostasis 
and inflammatory process. A study [173] demonstrated a correlation between PAR-2 
expression level and IgG aPL titers. Previous reports indicated a close relationship between 
TF and VEGF, protein involved in normal vascular development, as well pathogenesis 
related to inflammation and cardiovascular disease [174]. VEGF can be considered a 
regulatory factor in aPL Abs-mediated monocyte activation and TF expression, 
contributing to the proinflammatory-prothrombotic status of APS. 
TLR2, and TLR4 are membrane receptors known for their role in the activation of immune 
and ECs, pathogen recognition and cytokines production. TLR pathway activated in APS 
patients, in which PBMCs show a significant increase in the gene expression of TLR-2 and 
TLR-4 that mediate aPL Abs-induced vascular abnormalities. 
aPL Abs can also activate platelets, promoting its aggregation, thus contributing to the 
development of thrombosis. There are other potentially significant antigenic targets for 
aPL Abs, which include prothrombin, tissue plasminogen activator (tPA), PS, plasmin, 
annexin 2, activated protein (APC), thrombin, antithrombin III (AT-III), and annexin V. 
aPL Abs are associated to the development of atherosclerosis, and a direct correlation 
between serum levels of aCL and anti-β2GPI Abs and the occurrence of coronary 
syndrome myocardial infarction and stroke in vivo has been demonstrated [175]. 
A recent study found a strong association among higher aPL-IgG titers and development of 
thrombotic events, as well as with the presence of early atherosclerosis, as evidenced by an 
increased IMT [176]. Several studies confirmed the involvement of aPL Abs in the 
formation of the atheroma plaque in vitro, through the activation of ECs and leukocytes, 
and the induction of foam cell generation, by facilitating the adsorption of oxLDL by 
monocytes [177]. 
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β2-glycoprotein I 
 
β2GPI is major antigenic target of aPL Abs in both APS and SLE. It is a lipid-binding 
protein, 50 kDa β2 globulin involved in the regulation of blood coagulation [178] present 
in high levels, with largely unknown endogenous functions. 
 β2GPI possesses several properties that may bear relevance to progression of human 
atherosclerotic plaques; (1) it binds activated platelets and apoptotic cells upon exposure of 
inner-membrane PS; (2) it inhibits intrinsic blood coagulation pathway and ADP dependent 
platelet aggregation; (3) it serves as a key element in the activation of ECs induced by aPL 
Abs; and (4) it may cooperate in mediating the clearance of senescent cells and foreign 
particles from circulation [179]. 
β2GPI has good immunogenic properties, APS patient can produce Abs against several 
epitopes of the molecule. The presence of auto-Abs against β2GPI was described for the 
first time in 1990, when 3 different groups identified these Abs as an important 
subpopulation of auto-Abs in patients with APS [180-182]. 
The plasma glycoprotein β2GPI consists of 326 amino acids, arranged in 5 highly 
homologous complement control protein domains, designated domain I to V from the N-to 
the C-terminus. The first 4 domains consist of approximately 60 amino acids each, whereas 
the 5th domain is larger due to a 6-residue insertion and a 19-residue C-terminal extension 
that constitute a phospholipid binding loop [183]. The domain V, which resembles a 
“hook”, interacts with the PL in the cell bilayer; at the opposite end, domain I, is 
recognized by most clinically relevant Abs in APS [184]. 
 Depending on the redox state of the extracellular milieu, domains I and V expose different 
epitope surfaces for antibody binding (Fig.  3-4). A tight interaction between domains I 
and V, which defines the circular form of β2GPI in vivo, shields various epitopes on 
domain I. The dissociation between the two domains gives rise to the linear, fishhook-like 
structure of β2GPI in which domain I epitopes are exposed [185]. Cysteine residues at 
positions 288 and 326 of domain V, which either remain as free thiols or form a disulphide 
bond, control the conversion between the two alternative in vivo conformations. In the 
plasma of healthy individuals, β2GPI occurs in the free thiol form, which folds into a ring 
configuration and blocks antibody access to the principal domain I epitopes [186]. 
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 Figure 3. Schematic Representation of the Crystal Structure (Fishhook Configuration) of β2- 
Glycoprotein I (β2GPI) [Giannakopoulos, 2013]. 
 
 
In the plasma of healthy individuals, β2GPI occurs in the free thiol form, which folds into a 
ring configuration and blocks antibody access to the principal domain I epitopes [186]. 
Oxidative stress unfolds the ring conformation of β2GPI, exposing the normally shielded 
antigenic determinants of domain I, which are epitopes for pathogenic Abs binding [185]. 
This form inserts with domain V into the cell bilayer of anionic PL.  
The presence of Abs alone does not cause thromboembolic manifestations, the current 
view is that a “second hit” is necessary to determine a thrombotic event [187]. 
 In its circulating form, β2GPI is not recognized by pathologic anti-β2GPI Abs. Its 
recognition requires the conformational change that occurs either when it binds to 
negatively charged phospholipids exposed on a cell membrane, or because of oxidative 
stress [185]. Under these conditions, a cryptic epitope in the domain I of the molecule is 
exposed and recognized by these Abs. β2GPI is stabilized in this conformation, and the 
Abs-β2GPI complex can subsequently interact with several cellular surface receptors 
determining both vascular and obstetric events [187,188]. 
Raimondo et al. determined a strong positive correlation between IgG anti-domain I and 
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the proportion of oxidized β2GPI (oxβ2GPI), but not with IgM or IgA antidomain I [189]. 
This observation suggests that either anti-domain I IgG stabilizes the extended form of 
oxβ2GPI or that chronic inflammatory conditions lead to an abundance of oxβ2GPI that 
stimulates the production of anti-domain I IgG. 
β2GPI is present in atherosclerotic plaques from carotid arteries [179]. There is a direct 
binding of β2GPI to ECs and the activation of inflammatory receptors on these cells. 
The direct binding of β2GPI to ECs, a TLR4-mediated process, directly activates 
endothelia. Similarly, Laplante et al. [190] in a carotid artery injury model showed that 
anti-β2GPI activation of ECs is dependent on TLR4. The binding of β2GPI to TLR4 is 
enhanced by LPS and may reflect a possible scavenging of LPS. Current evidence 
indicates that autoimmunity can be detected within atherosclerotic lesions. 
 
 
 
Figure 4. How oxidized β2GPI participates in the formation of thrombotic APS. During 
oxidative stress, free thiol β2GPI can undergo post-translational modification to form the 
immunogenic form, oxidized β2GPI after binding phospholipids. β2GPI autoreactive CD4+ T cells 
recognize newly exposed epitopes located on Domain V but not on free thiol β2GPI. A complex is 
formed between aβ2GPI, autoreactive CD4+ T cells and oxidized β2GPI triggering the production 
of aPL, specifically aβ2GPI, cell proliferation and the release of pro-inflammatory cytokines which 
are key events in the pathophysiology of thrombotic APS [P.G. de Groot, 2017]. 
 
 
A previous work of our group has examined the role of Th1 specific inflammatory 
responses to β2GPI in established atherosclerotic lesions of primary APS patients. Their 
work demonstrated that plaque-derived, β2GPI-specific CD4+ T lymphocytes facilitate 
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perforin and Fas/Fas ligand-mediated cytotoxicity, pointing at a role for these auto-reactive 
T cells in plaque destabilization and potential athero-thrombotic events that are known to 
occur at a higher frequency in APS. They also demonstrated that β2GPI can induce 
proliferation and IFN-γ production by plaque-derived T cell clones. Furthermore, these T 
cells amplify monocyte responses, such as the production of TF and MMPs, which can be 
inhibited by an anti-IFN-γ antibody [191]. 
 Pathogenic SLE immune response and the development of atherosclerotic plaques share 
some characteristics due to skewed T cell activation. aPL increase the risk of vascular 
events and death in SLE [171]. 
It has been hypothesized that the development of an anti-β2GPI-specific response in the  
target organ may contribute to atherothrombosis in SLE-APS patients. This hypothesis is 
largely based on the presence of β2GPI in human atherosclerotic plaques [179] and on the 
enhanced fatty streak formation in transgenic atherosclerosis-prone mice immunized with 
β2GPI [192,193]. Moreover, β2GPI-reactive T cells also promote early atherosclerosis in 
LDLR–deficient mice [194]. 
β2GPI is a target auto-Ag in both SLE and APS with good immune properties and seems to 
play a pathogenic role in atherosclerosis. 
β2GPI is able to induce events leading to the stimulation of a specific T cell immune 
response in the atherosclerotic lesions of patients with SLE-APS or triple positive aPL 
Abs. The loss of local tolerance in atherosclerotic plaques and the increased plaque 
inflammatory process are important risk factors for clinical events. 
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The potential therapeutic strategies in SLE that target the immune system, and their 
impact on atherosclerosis and CVD: Novel immune-based therapies for CVD 
 
CVD is an important complication of SLE, and effective preventive measures remain to be 
identified. The suggested novel target therapies are based on the pathogenic immune 
responses in SLE and the development of atherosclerotic plaques (Fig. 5), which share 
some similar characteristics, such as impaired efferocytosis and skewed T cell activation. 
Impaired efferocytosis, a common link between SLE and atherosclerosis, the loss of 
tolerance against LDL and other plaque Ags in atherosclerosis shares many characteristics 
with the loss of tolerance against self-Ags associated with disease development and organ 
damage in SLE. In particular, an impaired capacity to clear apoptotic cells and necrotic 
debris has been implicated as an important factor in both diseases [195]. 
The novel immune-based therapies for CVD are being developed and tested in clinical trial 
[196], it is likely that some of these may also show efficacy for the treatment of SLE. Novel 
immune-based therapies for CVD are being developed and may be effective in the 
prevention of CVD and in immunomodulation. Immunosuppressive drugs may reduce the 
progression of atherosclerosis and cardiovascular events, yet their exact mechanisms 
require further elucidation. To date monoclonal Abs like Belimumab have proven efficacy 
in the treatment of lupus nephritis [197] and several others monoclonal Abs like 
secukinumab, ixekizumab, and bimekizumab, which are IL-17A pathway blockers, and 
brodalumab an anti-17RA are approved for some immune-mediated inflammatory diseases 
[198]. 
 In SLE Th17 cells produce IL-17, IL-21, and IL-22 and are involved in the development 
of inflammation in various organs. IL-17-producing cells play a crucial role in the disease 
pathogenesis and represent an attractive therapeutic target. Several IL-17A pathway 
blockers, there are preclinical and clinical studies that suggest a critical role of IL-23/IL-17 
axis in SLE pathogenesis. Further studies, including a phase III study with ustekinumab, 
are needed to initiate the use of blockers of the IL23/IL-17 pathway in the treatment of 
SLE patients. Blocking IL-17 and/or Th17 cells might be beneficial in SLE but the effects 
in atherosclerosis and CVD are more uncertain and need to be carefully investigated [199]. 
 Immunomodulation in atherosclerosis can basically have three targets: enhancing anti-
inflammatory mechanisms, inhibiting cholesterol synthesis, and immunization against neo-
Ags. In SLE there is an aberrant T cell signalling and there are many pathways involved in 
the disease and in atherosclerosis development. The possibility of using T1 IFN as a target 
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for future SLE therapies is currently under investigation. An anti-IFN-α monoclonal 
antibody was found to be safe, well tolerated, and effective and will be further investigated 
in clinical trials. Vaccination strategies leading to induction of anti-IFN-α Abs are also 
under development [200]. As T1 IFN also have a disease-promoting role in atherosclerosis, 
the blocking of these cytokines may be beneficial in CVD, both in SLE patients and in 
subjects without SLE. 
 
 
 
  
 
Figure 5. Potential future therapies targeting the immune system in systemic lupus erythematous 
(SLE) and cardiovascular disease (CVD) [Wigren, 2015]. 
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AIM OF THE STUDY 
 
 
This study was undertaken to evaluate the type of T cells responses elicited by β2GPI in 
established atherosclerotic lesions with SLE-APS patients. We investigated the cytokine 
production induced by β2GPI in activated T cells that infiltrate in vivo atherosclerotic 
lesions of SLE-APS patients. We examined the helper function of β2GPI-specific T cells 
for the TF production, as well as their cytolytic potential and their helper function for Abs 
production. 
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MATERIALS AND METHODS 
 
 
Patients 
 
Upon approval of the local Ethical Committee, 10 patients (10 females, mean age 51; range 
42-56 years) with SLE-APS, 10 aPL Abs negative patients (10 females, mean age 51, 
range 43-55), 5 SLE aPL Abs positive patients (5 females, mean age 49, range 44-53), and 
5 SLE aPL-negative patients (5 females, mean age 50, range 44-56), all affected by carotid 
atherosclerotic arteriopathy were included in the study. The carotid plaques were obtained 
by endarterectomy from each patient. The clinical informations of each patient are reported 
in (Table 3-6). 
All patients studied (SLE- APS, SLE aPL Abs-positive, SLE aPL Abs-negative and aPL 
negative patients) were eligible for vascular surgery. SLE-APS patients were triple positive 
for aPL Abs, with high titters serum anti-β2GPI, aCL Abs and with positivity for LA. All 
SLE-APS patients in this study satisfied the Myiakis’s criteria for APS, and they were on 
oral anticoagulation with vitamin K antagonists, then switched to low molecular weight 
heparin few days before surgery [160]. None of them displayed traditional risk factors for 
atherosclerosis and they were not receiving any anti-lipidemic drugs. All the SLE aPL-
positive patients were affected by SLE but not by APS, although they were positive for 
aPL, with serum anti-β2GPI, anti-cardiolipin Abs or with positivity for LA. All SLE aPL-
neg patients were affected by SLE but not by APS, and they were triple negative for serum 
aPL, such as anti-β2GPI, aCL Abs and with negativity for LA. 
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Patients 
 
 
Age 
 
 
Sex 
 
 
Treatment 
 
 
SLEDAI 
 
 
Autoanti 
bodies 
 
 
Total 
clones 
Total 
No. of 
CD8⁺ 
clones 
No. of 
CD8⁺ 
clones 
reactive 
to β2GPI 
Total 
No. of 
CD4 
clones 
No. of 
CD4⁺ 
clones 
reactive 
to β2GPI 
A 42    F a+b 7 c+d+e 38 5      0 33 8 
B 56    F a+b 8 c+d+e+f 34 4      0 30 6 
C 51    F    b 7 c+d 33 6      0 27 6 
D 50    F    b 5    e 31 1      0 30 8 
E 50    F    b 8 c+d+e 32 4      0 28 7 
F 54 F a+b 6 c+d+g 34 3      0 31 7 
G 55 F    b 7 c+d+h 35 3      0 32 8 
H 48 F a+b 7     c+d+e 30 3      0 27 7 
 I 49 F     b 8 c+d+e+h 36 4     0 32 8 
L 55 F a+b 6 c+d 31 4     0 27 6 
 
Table 3. Clinical and lab information of the 10 SLE-APS patients. All the 10 patients shown in 
this table were affected by SLE-APS and were triple positive for aPL, with high titers serum anti-
β2GPI, aCL and with positivity for Lupus Anticoagulant. a: treated with hydroxychloroquine; b: 
treated with glucocorticoids; c: ANA-positive; d: anti-SSA-positive; e: anti-ds DNA-positive; f: 
anti-SSB-positive; g: anti-U1 RNP-positive; h: anti-Sm-positive. 
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Patients 
 
 
Age 
 
 
Sex 
 
 
Treatment 
 
 
SLEDAI 
 
 
Autoanti 
bodies 
 
 
Total 
clones 
Total 
No. of 
CD8⁺ 
clones 
No. of 
CD8⁺ 
clones 
reactive 
to β2GPI 
Total 
No. of 
CD4 
clones 
No. of 
CD4⁺ 
clones 
reactive 
to β2GPI 
M 43 F none 0 none 39 5 0 36 0 
N 55 F none 0 none 37 4 0 33 0 
O 51 F none 0 none 29 7 0 22 0 
P 50 F none 0 none 28 4 0 24 0 
      Q 50 F none 0 none 36 4 0 32 0 
R 54 F none 0 none 31 3 0 28 0 
S 55 F none 0 none 38 5 0 33 0 
T 48 F none 0 none 26 3 0 23 0 
U 49 F none 0 none 34 5 0 27 0 
     V 55 F none 0 none 32 2 0 30 0 
 
Table 4. Clinical and lab information of the 10 aPL-neg patients. All the 10 patients shown 
in this table were affected by carotid atherosclerotic arteriopathy but not by SLE-APS and were 
triple negative for serum aPL, such as anti-β2GPI, aCL and with negativity for Lupus 
Anticoagulant, and they were all negative for any autoantibody. They were not treated with any 
steroids, nor other immune- suppressants. 
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Patients 
 
 
Age 
 
 
Sex 
 
 
Treatment 
 
 
SLEDAI 
 
 
Autoantibo
dies 
 
 
Total 
clones 
Total 
No. 
ofCD
8⁺ 
clones 
No.of 
CD8⁺ 
clones 
reactive 
to β2GPI 
Total 
No. of 
CD4 
clones 
No. of 
CD4⁺ 
clones 
reactive 
to 
β2GPI 
Y 44 F a+ b 6 c+d 32 4 0 28 4 
YA 53 F b 9 c+e 28 3 0 24 3 
YB 52 F b 8 c+d+e 25 5 0 20 5 
YC 48 F a+b  7 c+d 34 3 0 31 6 
YD 49 F a+ b 5 c+d+e+f 38 6 0 32 7 
 
Table 5. Clinical and lab information of the 5 SLE aPL-pos patients. All the 5 patients shown 
in this table were affected by SLE but not by APS, although they were positive for aPL, with serum 
anti-β2GPI, aCL or with positivity for Lupus Anticoagulant. a: treated with hydroxychloroquine; b: 
treated with glucocorticoids; c: ANA-positive; d: anti-SSA-positive; e: anti-ds DNA-positive; f: 
anti-SSB-positive; g: anti-U1 RNP-positive; h: anti-Sm-positive. 
 
 
 
 
 
 
 
 
 
Patients 
 
 
Age 
 
 
Sex 
 
 
Treatment 
 
 
SLEDAI 
 
 
Autoanti 
bodies 
 
 
Total 
clones 
Total 
No. of 
CD8⁺ 
clones 
No. of 
CD8⁺ 
clones 
reactive 
to β2GPI 
Total 
No. of 
CD4 
clones 
No. of 
CD4⁺ 
clones 
reactive 
to 
β2GPI 
Z 52 F b 7 c+d+e 29 5 0 26 0 
   ZA 49 F a+b 9 c+e+g 34 4 0 28 0 
ZB 51 F a+b 8 c+e+h 31 7 0 24 0 
ZC 44 F b 6 c+h+g 39 6 0 33 0 
ZD 56 F b 7   c+e+h 33 8 0 25 0 
 
Table 6. Clinical and lab information of the 5 SLE aPL-neg patients. All the 5 patients shown 
in this table were affected by SLE but not by APS, and they were triple negative for serum aPL, 
such as anti-β2GPI, aCL and with negativity for Lupus Anticoagulant. a: treated with 
hydroxychloroquine; b: treated with glucocorticoids; c: ANA-positive; d: anti-SSA-positive; e: 
anti-ds DNA-positive; f: anti-SSBpositive; g: anti-U1 RNP-positive; h: anti-Sm-positive. 
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Reagents 
 
Human β2GPI was purified by perchloric acid treatment of pooled normal human sera 
obtained from blood donors followed by affinity purification on Heparin column (HiTrap 
Heparin HP, GE Healthcare, Milan, Italy) and by ion-exchange chromatography 
(Resource-S, GE Healthcare) [201].  
We also ruled out the presence of contaminants by a limulus test. The human β2GPI used 
has been tested with a limulus test and resulted negative throughout the whole study. 
Human recombinant (hr)IL-2 and tetanus toxoid (TT) were provided by Novartis, Siena, 
Italy. Phytohaemagglutinin (PHA) was purchased from Life Technologies (Carlsbad, CA). 
Fluorochrome-conjugated human monoclonal antibodies (mAbs) anti-CD3, anti-CD4, anti-
CD8, anti-IFN-γ and isotype-matched control mAb were purchased from BD Biosciences 
(San Jose, CA, USA).The fluorochrome conjugated anti-IL-17 mAb was obtained from 
eBioscience (San Diego, CA, USA). PMA, ionomycin and brefeldin A were purchased 
from BD Biosciences (San Jose, CA, USA). 
 
 
Anti-phospholipid antibody detection 
 
For the detection of aCL and aβ2GPI in patient sera, commercially available solid-phase 
ELISA employing purified human β2GPI in complex with CL and human β2GPI were 
used (Inova, Ca, USA). 
 Sera were considered positive when their concentration exceeded the cut-off of 10 U/mL 
for IgG and IgM. All samples were tested by the respective in-house assay as Described 
elsewhere [202]. 
 The results of the two techniques were comparable. Analysis of LA was performed in 
accordance with the international recommendations as described [203]. 
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Generation and characterization of T cell clones from atherosclerosis plaque’ 
inflammatory infiltrates 
 
Induction of T lymphocyte lines from atherosclerotic plaques in order to preferentially 
expand in vivo- activated T cells in vitro. A biopsy specimen of carotid plaques, obtained 
by endarterectomy, were investigated in both SLE-APS and in aPL negative patients under 
the same experimental conditions. 
 Plaque fragments were immediately cultured for 7 days with hrIL-2 (50 U/ml) in RPMI 
1640 complete medium (supplemented with L-glutamine 1%, beta-mercaptoethanol 1%, 
Na-pyruvate 1%, non-essentialaminoacids 1%, penicillin 50.000U and streptomycin 50 
mg), heat-inactivated human serum 3%, and fetal bovine serum (FBS)10%. After 7 days of 
culture the vital T lymphocyte found in medium were used to generate clones. 
Specimens were then disrupted, and single T cells blasts were cloned under limiting 
dilution, (0.3 cells/well) in round-bottom microwell plates containing 10⁵ irradiated PBMC 
(as feeder cells) in final volume in 0.2 ml of medium RPMI complete; added PHA (0.5% 
v/v), and hrIL-2 (30U/ml), After one week 0.1 ml of medium containing new feeder cells ( 
irradiate PBMCs ) (10⁵/well)  and  hrIL-2 (30U/ml) was added to microculture [204,205]. 
 This procedure was repeated at intervals weekly, after three weeks the originated clones 
were expanded and T cell blasts were used to assess their phenotype profile, T cell clones 
were screened by flow cytometry with fluorochrome conjugated anti-CD3, anti- CD4, anti-
CD8 on a BD FACSCanto II (BD Bioscience), using the FACS Diva 6.1.3.software. 
The repertoire of the TCR Vβ chain of β2GPI-specific Th clones was analysed with a panel 
of mAbs specific to the following: Vβ1, Vβ2, Vβ4, Vβ5.1, Vβ5.2, Vβ5.3, Vβ7, Vβ8,Vβ9, 
Vβ11, Vβ12, Vβ13.1, Vβ13.2 and Vβ13.6, Vβ14, Vβ16, Vβ17, Vβ18, Vβ20, Vβ21.3, 
Vβ22,and Vβ23 (Beckman Coulter); Vβ6.7 (Gentaur) and Vβ3.1 (In Vitro Gen). 
 Isotype-matched nonspecific Ig were used as negative control. Vβ10, Vβ15, and Vβ19 T 
cell receptor typing were investigated by Clontech kit, according to the manufacturer's 
instructions. 
T cell clones were then analyzed for their responsiveness to β2GPI by measuring [3H] 
thymidine uptake after 60 h of co-culture with irradiated autologous PBMCs in the 
presence of medium, or β2GPI (10 nM). The mitogenic index (MI) was calculated as the 
ratio between mean values of counts per minute (cpm) obtained in stimulated cultures and 
those obtained in the presence of medium alone. MI >5 was considered as positive. 
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Assessment of T cell clones cytokine profile 
 
To assess the cytokine production of β2GPI-specific T cell clones upon antigen 
stimulation, 5 × 10⁵ T cell blasts of each clone were co-cultured for 48 h in 0.5 ml of 
serum-free medium with 5 × 10⁵ irradiated autologous PBMCs in the absence or presence 
of β2GPI (10 nM). At the end of the culture period, duplicate samples of each supernatant 
were assayed for their IFN-γ, TNF-α, IL-4, IL-21 and IL- 17 (BioSource International, 
Camarillo, CA) production by ELISA. For further investigation, T cell blasts from each 
β2GPI-specific T cell clone were stimulated with medium or β2GPI (10 nM) in the 
presence of autologous APCs for 48 h in ELISpot microplates coated with anti-IFN-γ or 
anti-IL-17 antibody, respectively (eBioscience, Inc., San Diego, Ca, USA).  At the end of 
culture period, the number of IFN-γ and IL-17 SFCs were counted by using an automated 
reader as described [206].  
T helper assay to assess their ability to induce TF production and procoagulant activity 
(PCA) in autologus monocytes. T cell blasts (8 × 10⁵ / ml) of β2GPI-specific T cell clones 
were co-cultured for 16 hrs with autologous monocytes (4 × 10⁵ / ml) in the presence of 
serum-free medium or β2GPI (10 nM). At the end of the culture period, the amount of TF 
protein was quantitated by a specific ELISA (American Diagnostica, Greenwich, CT) in 
duplicate samples of supernatants obtained from cell suspensions after solubilization of 
membrane proteins with Triton X-100 and ultracentrifugation. 
 At the end of culture period, cell suspensions consisting of monocytes alone, or monocytes 
plus activated T cells were disrupted by repeated freezing and thawing followed by 
sonication. 
 Total cellular content of PCA was determined in a one-stage clotting assay and expressed 
in arbitrary units (U/10⁵ monocytes) assigned by comparison with a standard curve derived 
from rabbit brain thromboplastin standard (Manchester Comparative Reagents, 
Manchester, UK) [206]. 
Our log-log plot was linear up to 200 seconds clotting time. Values less than 10 U/10⁵ 
monocytes corresponded to clotting times ranging from 170 to 80 seconds. One thousand 
units corresponded to approximately 22 seconds clotting time. 
 PCA was characterized as factor VII-dependent procoagulant activity by evaluating its 
sensitivity to phospholipase C (Calbiochem, San Diego, CA), concanavalin A, and cysteine 
protease inhibitor (HgCI2), and by using factor VII- and factor X-deficient plasma samples 
[207]. 
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T cell clones' helper assay to evaluate the induction of immunoglobulin (Ig) 
production by autologous B cell 
 
T cell blasts of each clone were co-cultured at ratios of 0.2, 1, and 5 to 1 with autologous 
PBMCs in the absence or presence of β2GPI and, on day 10, culture supernatants were 
harvested and tested for the presence of IgM, IgG, and IgA by ELISA, Results represent 
the mean value (+/–SE) of Ig levels induced by T cell clones compared to the Ig 
spontaneous production in B cell cultures alone [208]. 
 
 
 
Statistical analysis 
 
Statistical analyses were performed using Student’s t test; data were considered significant 
if P values > 0.05. 
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RESULTS 
 
 
Atherosclerotic lesions of SLE-APS patients and SLE aPL-positive patients harbour 
autoreactive β2GPI-specific CD4+ T cell clones 
Atherosclerotic plaque-infiltrating in vivo activated T cells were expanded in vitro in an 
hrIL-2 conditioned medium, subsequently cloned and studied for their phenotypic and 
functional profile. A total number of 297 CD4+ and 37 CD8+ T cell clones were obtained 
from atherosclerotic lesions of 10 SLE-APS patients. For each patient, CD4+ and CD8+ 
atherosclerotic lesion-derived T cell clones were assayed for proliferation in response to 
medium, or β2GPI. None of the CD8+ T cell clones showed proliferation to β2GPI although 
they proliferated in response to mitogen stimulation (Fig. 6). 
We have also investigated the amount of β2GPI-specific T cells present in the peripheral 
blood of SLE-APS patients and compared it with the one found in atheromas. The 
proportion of β2GPI- specific CD4+ T cell clones generated from atherosclerotic plaques of 
SLEAPS patients was 24%, which is remarkably higher compared with the frequency of 
β2GPI-specific T cells found in the peripheral blood of the same patients (between 1:1900 
and 1:3400). Each β2GPI-reactive CD4+ T cell clone was stained by only one of the TCR-
Vβ chain–specific monoclonal antibodies, showing a single peak of fluorescence intensity 
(Fig. 7). T cell blasts were used to assess their cytokine profile. The analysis was 
performed using FACS Canto II (BD). Dot plots expression of IFN-γ+ and IL-17+ on CD4+ 
T cells of the 10 T cell lines obtained from the 10 SLE-APS patients (Fig. 8). 
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Figure 6. Antigen specificity of atherosclerotic plaque CD4⁺ T and CD8⁺ T cell clones 
obtained from SLE-APS patients. T cell clones were analysed for responsiveness to β2GPI (10 
nM) (■), or medium (□) by measuring [3H] Thymidine uptake after 60 h of co-culture with 
irradiated autologous PBMCs. 71 out of 297 CD4+ T cell clones proliferated in response to β2GPI 
and are shown in panel A. None of the 37 CD8+ T cell clone proliferated to β2GPI (panel B). 
 
 
 
 
Figure 7. TCR Vβ chain r e p e r t o i r e  of β2GPI-specific T cell clones derived from the 
atherosclerotic plaques of SLE-APS patients. All clones obtained from two representative 
patients, named “A” and “B”, are represented in the figure. 
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Figure 8. IFN-γ and IL-17 intra-cellular cytokine staining of plaque-infiltrating T cells of 
SLE -APS patients. Cells were stained for surface and intracellular markers with the following 
mAbs for flow cytometry: anti-CD4-PerCP, anti-IL-17-PE, and anti-IFN-γ-FITC (Becton 
Dickinson). Samples obtained from the atherosclerotic lesions of each of the SLE-APS patients 
were stimulated with PMA (25ng/ml) plus1μγ/ml ionomycinin the presence of brefeldin A 
(1μg/ml). The analysis was performed using FACS Canto II (BD), by the acquisition software 
FACS Diva 6.1.3. For each sample 5000 events were acquired. Dot plots expression of IFN-γ+ and 
IL-17+ on CD4+ T cells of the 10 T cell lines obtained from the 10 SLE-APS patients (named A, B, 
C, D, E, F, G, H, I, L) are shown. 
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Seventy-one (24%) of the 297 CD4+ T cell clones generated from SLE-APS atherosclerotic 
plaque- infiltrating T cells proliferated significantly to β2GPI (Fig. 6). Each SLE-APS 
patient displayed a comparable percentage of CD4+ T cell clones responsive to β2GPI 
(Table 3). On the other hand, a total number of 288 CD4+ and 42 CD8+ T cell clones were 
obtained from atherosclerotic lesions of10 atherothrombotic patients, that were negative for 
aPL. For each patient, CD4+ and CD8+atherosclerotic lesion-derived T cell clones were 
assayed for proliferation in response to medium or β2GPI. None of the CD4+ or CD8+ T 
cell clones derived from the atherosclerotic lesions showed proliferation to β2GPI (Table 
4). A total number of 135 CD4+ and 21 CD8+ T cell clones were obtained from 
atherosclerotic lesions of 5 SLE aPL-positive. For each patient, CD4+ and 
CD8+atherosclerotic lesion-derived T cell clones were assayed for proliferation in response 
to medium or β2GPI. 25 CD4+ and no CD8+ T cell clones derived from the atherosclerotic 
lesions of SLE aPL- positive patients showed proliferation to β2GPI (Table 5). A total 
number of 136 CD4+ and 30 CD8+ T cell clones were obtained from atherosclerotic lesions 
of 5 SLE aPL-negative. For each patient, CD4+ and CD8+ atherosclerotic lesion-derived T 
cell clones were assayed for proliferation in response to medium or β2GPI. None of the 
CD4+ or CD8+ T cell clones derived from the atherosclerotic lesions showed proliferation 
to β2GPI (Table 6). 
All β2GPI-specific T cell clones, both those obtained from the atherosclerotic lesions of 
SLE-APS patients and those obtained from SLE aPL-positive patients, were stimulated 
with β2GPI and autologous APCs. Then, TNF-α and IL-4, IFN-γ and IL-17 production was 
measured in culture supernatants. In unstimulated cultures, level of TNF-α. IL-4, IFN-γ 
and IL-17 were consistently < 20pg/ml. 
Upon antigen stimulation with β2GPI of the 71 β2GPI-specific T cell clones obtained from 
SLE- APS patients, 30 were polarized Th1 clones (CD4+ T cell clones producing IFN-γ, 
but not IL-17 nor IL-4 were coded as Th1), 10 Th clones were Th17 (CD4+ T cell clones 
producing IL-17, but not IFN-γ nor IL-4 were coded as Th17), 27 Th clones were 
Th17/Th1 (CD4+ T cell clones producing IFN-γ, and IL-17, but not IL-4 were coded as 
Th17/Th1), and only 4 were able to produce IL-4 together with TNF-α (Th0 clones) (Fig. 
9). Upon antigen stimulation with β2GPI of the 25 β2GPI-specific T cell clones obtained 
from SLE aPL positive patients, 10 were polarized Th1 clones, 6 Th clones were polarized 
Th17, 8 Th clones were Th17/Th1 and only 1 was Th0 (Fig. 10). 
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T cell blasts from each of the 71 β2GPI-reactive T cell clones obtained from 
atherosclerotic lesions of patients with SLE-APS were further screened by IFN-γ and IL-17 
ELISpot in response to β2GPI (Fig. 11). Upon appropriate stimulation, IFN-γ SFCs were 
then counted by using an automated reader. After specific stimulation, 61/71 β2GPI-
specific atherosclerotic plaque-derived T cell clones produced IFN-γ. Values are the 
mean ± SD number of SFCs per 105 cultured cells over background levels. IL-17 SFCs 
were then counted by using an automated reader. After specific stimulation 37/71 
β2GPI-specific atherosclerotic plaque-derived T cell clones produced IL-17. Values 
are the mean ± SD number of SFCs per 105 cultured cells over background levels. 
61 atherosclerotic derived atherosclerotic derived CD4+ T cell clones produced IFN-γ, and 
thirty-seven produced IL-17 (Fig. 12). Interestingly, all IL-17-producing β2GPI-reactive T 
cell clones, produce IL-21 (mean ± SE, 3.3±0.5 ng/ml per 106 T cells) in response to  
antigen stimulation. 
 
 
 
 
Figure 9. Cytokine profile of atherosclerotic plaque β2GPI-specific CD4+ T cell clones 
obtained from SLE-APS patients. Th clones were tested for cytokine production (A-B). 
β2GPI-specificTh clones were stimulated with β2GPI and TNF-α and IL-4, IFN-γ and IL-17 
production was measured in culture supernatants. In unstimulated cultures, levels of TNF-α, IL-
4, IFN-γ and IL-17 were consistently < 20 pg/ml. CD4+ T cell clones producing IFN-γ, but not 
IL-17 nor IL-4 were coded as Th1. CD4+ T cell clones producing IL-17, but not IFN-γ nor IL-4 
were coded asTh17. CD4+ T cell clones producing IFN-γ, and IL- 17, but not IL-4 were coded 
as Th17/Th1. CD4+T cell clones producing TNF-α and IL-4, but not IL-17 were coded asTh0. 
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Figure 10. Cytokine profile of atherosclerotic plaque β2GPI-specific CD4+ T cell 
clones obtained from SLE-aPL-positive patients. Th clones were tested for cytokine 
production (A-B). β2GPI-specific Th clones were stimulated with β2GPI and TNF-α and 
IL-4, IFN-γ and IL-17 production was measured in culture supernatants. In unstimulated 
cultures, levels of TNF-α, IL-4, IFN-γ and IL-17 were consistently < 20 pg/ml. CD4+ T 
cell clones producing IFN-γ, but not IL-17 nor IL-4 were coded as Th1. CD4+ T cell 
clones producing IL-17, but not IFN-γ nor IL-4 were   coded as Th17. CD4+T cell clones 
producing IFN-γ, and IL-17, but not IL-4 were coded asTh17/Th1. CD4+ T cell clones 
producing TNF-α and IL-4, but not IL-17 were coded as Th0. 
 
 
                         
 
. 
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Figure 11. β2GPI driven IFN-γ and IL-17 secretion by β2GPI-specific atherosclerotic plaque 
derived Th clones from SLE-APS patients. Numbers of IFN-γ spot-forming cells (SFCs) after 
stimulation of atherosclerotic plaque derived T cell clones with medium alone, or β2GPI (A). T cell 
blasts from each clone were stimulated for 48 h with medium alone (□), or β2GPI (■), in the 
presence of irradiated autologous APCs in ELISpot microplates coated with anti-IFN-γ antibody. 
IFN-γ SFCs were then counted by using an automated reader. After specific stimulation, 61/71 
β2GPI-specific atherosclerotic plaque-derived T cell clones produced IFN-γ. Values are the mean ± 
SD number of SFCs per 10⁵ cultured cells over background levels. 
Numbers of IL-17 spot-forming cells SFCs after stimulation of atherosclerotic plaque derived T cell 
clones with medium alone, or β2GPI (B). T cell blasts from each clone were stimulated for 48 h 
with medium alone (□), or β2GPI (■) in the presence of irradiated autologous APCs in ELISpot 
microplates coated with anti-IL-17 antibody. IL-17 SFCs were then counted by using an automated 
reader. After specific stimulation 37/71 β2GPI-specific atherosclerotic plaque-derived T cell clones 
produced IL-17. Values are the mean ± SD number of SFCs per 10⁵ cultured cells over background 
levels. 
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Figure 12. β2GPI driven IFN-γ and IL-17 secretion by β2GPI-specific atherosclerotic plaque 
derived T-cells from SLE-APS patients. Atherosclerotic plaque-derived T-cell lines were 
expanded from SLE-APS patients by addition of IL-2. At day 7, T-cell blasts from each line were 
stimulated for 48 h with ß2GPI or medium, in the presence of irradiated autologous APCs in 
ELISpot microplates coated with anti-IFN-γ anti-IL- 17, or anti-IL-4 antibodies. After specific 
stimulation with ß2GPI, a significant proportion of SLE- APS atherosclerotic plaque-derived Th 
cells produced IL-17 and IFN-γ, but not IL-4. Values are the mean ± SD number of SFCs per 10⁵ 
cells over background levels. 
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β2GPI-specific atherosclerotic lesion-infiltrating T cells help monocyte TF production 
and PCA 
 
Plaque rupture and consequent thrombosis are crucial complications of atherosclerosis. TF 
plays a key role in triggering atherothrombotic events being the primary activator of the 
coagulation cascade. We investigated whether atherosclerotic lesion-infiltrating β2GPI-
specific T cells had the potential to express helper functions for TF production and PCA by 
autologous monocytes. Antigen-stimulated β2GPI-specific atherosclerotic lesion-derived T 
cell clones were co-cultured with autologous monocytes in the presence of medium or 
β2GPI. and levels of TF and PCA were measured by ELISA. Antigen stimulation resulted 
in the expression of substantial help for TF (Fig. 13A) production and PCA (Fig. 13B) by 
autologous monocytes. 
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Figure 13. Induction of TF synthesis and PCA by atherosclerotic plaque β2GPI-specific T 
cells derived from SLE-APS patients. Atherosclerotic plaque β2GPI-specific T cells induce TF 
production and PCA by autologous monocytes. To assess their ability to induce TF production 
and PCA by autologous monocytes, β2GPI-specific Th clones were co-cultured with autologous 
monocytes in the presence of medium (□) or β2GPI (■) (A). TF production by monocytes was 
assessed by ELISA. The results shown represent TF levels induced by T cell clones over the TF 
production in cultures of monocytes alone. Atherosclerotic plaque-derived β2GPI-specific T cell 
induced PCA in autologous monocytes (B). β2GPI-specific Th clones were co-cultured with 
autologous monocytes in the presence of medium (□) or β2GPI (■). At the end of the culture 
period, cells were disrupted and total PCA was quantitated as reported in Materials and Methods. 
The results shown represent PCA induced by T cell clones in monocytes over the PCA in cultures 
of monocytes alone. 
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Atherosclerotic lesion-derived β2GPI-specific T cell clones express antigen-dependent 
help to autologous B cells for Ig production 
 
T-B cell interaction is a multistep process resulting in B cell help depending on the 
functional commitment of the Th cells involved. So far, the ability of SLE-APS-derived 
β2GPI-specific T cell clones to provide B cell help for Ig synthesis was investigated. In the 
absence of the specific antigen, no increase in IgM, IgG, or IgA production above 
spontaneous levels measured in cultures containing B cells alone was observed. In the 
presence of β2GPI and at a T-to-B cell ratio of 0.2 to 1, all of the β2GPI-specific T cell 
clones provided substantial help for Ig production. At a 1-to-1 T/B cell ratio, β2GPI-
dependent T cell help for IgM, IgG, and IgA production by B cells was remarkably higher 
(Fig. 14). However, at a 5-to-1 T/B cell ratio, co-culturing B cells with autologous β2GPI-
specific T cell clones in the presence of β2GPI resulted in a much lower Ig synthesis. 
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Figure 14. Helper function of atherosclerotic plaque β2GPI-specific T cells derived from 
SLE-APS patients. Autologous peripheral blood B cells (5 x 10⁴) were co-cultured with β2GPI- 
specific T cell blasts at a T:B ratio of 0.2, 1, and 5 to 1 in the absence (□) or presence of β2GPI 
(■). After 10 days, culture supernatants were harvested and tested for the presence of IgM, IgG, 
and IgA by ELISA. Results represent the mean value (+/–SE) of Ig levels induced by T cell 
clones compared to the Ig spontaneous production in B cell cultures alone. 
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Atherosclerotic lesion-derived β2GPI-specific T cell clones display cytotoxic and 
proapoptotic activity. 
 
The cytolytic potential of SLE-APS-derived atherosclerotic lesion-derived β2GPI-specific 
autoreactive T cell clones was assessed by using antigen-pulsed ⁵¹Cr-labeled autologous 
EBV-B cells as targets. At an E:T ratio of 10:1, all Th1 and Th17/Th1 specific T cell 
clones were able to lyse β2GPI-presenting autologous EBV-B cells (range of specific ⁵¹Cr 
release, 35–65%), whereas autologous EBV-B cells pulsed with control Ag and co-cultured 
with the same clones were not lysed (Fig. 15A). Likewise, 2 Th0 and all Th17 specific T 
cell clones were able to lyse their target (specific ⁵¹Cr release, 50% and 25-45% 
respectively), while no lysis was observed when using autologous EBV-B cells pulsed with 
the control Ag. 
Fas-FasL mediated apoptosis was assessed using Fas+ Jurkat cells as target. T cell blasts 
from each clone were co-cultured with ⁵¹Cr-labeled Jurkat cells at an E: T ratio of 10, 5, 
and 2.5 to 1 for 18 h in the presence of PMA and ionomycin (Fig. 15B). Upon mitogen 
activation, 27 out of 30Th1, 24/27 Th17/Th1, 4/10 Th17, and 2 out of 4 Th0 clones were 
able to induce apoptosis in target cells (range of specific ⁵¹Cr release, 25-61%). 
 
  
 
Figure 15. Cytotoxic and pro-apoptotic activity of β2GPI-specific atherosclerotic 
plaquederived CD4+ T cells derived from SLE-APS patients. (A) To assess their 
cytotoxicity, β2GPIspecific CD4+ T cell clones were co-cultured at different E:T ratios with 
⁵¹Cr-labeled autologous EBV-B cells pulsed with β2GPI (■) or medium alone (□).  ⁵¹Cr release 
was measured as index of specific target cell lysis. 
(B) To assess their ability to induce apoptosis in target cells, β2GPIspecific CD4+ T cell clones 
stimulated with mitogen (■) or medium alone (□) were co-cultured with ⁵¹Cr-labeled Fas+Jurkat 
cells, and ⁵¹Cr release was measured as the index of apoptotic target cell death. 
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DISCUSSION 
 
 
Several clinical studies and experimental models suggest a role for aPL in accelerating 
atherosclerotic plaque formation in SLE. On the other hand, there is growing evidence that 
aPL represent a risk factor for arterial thrombosis supporting their pathogenic role in 
cardiovascular events [64, 177, 209, 210]. Here in we report for the first time that a pro-
inflammatory and procoagulant β2GPI-specific Th17, Th1 and Th17/Th1 infiltrate in 
human atherosclerotic lesions of patients with SLE-APS and may represent a key 
pathogenic atherothrombotic mechanism. 
Many self-Ags, such as oxLDL, may theoretically be involved in SLE-APS 
atherosclerosis; oxLDL-specific peripheral blood-derived T cells displaying a Th1 profile 
were reported in APS patients [211]. However, there is no information on whether these 
cells are actively involved in atherosclerotic tissue lesions of SLE-APS patients. In 
addition, β2GPI was found to bind oxLDL [88] raising the issue whether or not the 
immune response is against oxLDL or β2GPI itself. 
The relevance of the data presented in this study consists in the demonstration that all ten 
SLE-APS patients with clinically severe atherothrombosis harbored in their target tissues, 
such as atherosclerotic lesions, in vivo-activated CD4+ T cells able to react to β2GPI. CD4+ 
T cells specific for β2GPI were found also in the plaques of SLE aPL-positive patients but 
not in SLE aPL-negative patients nor in atherosclerotic patients without SLE. The results 
suggested that β2GPI drive inflammation in atherosclerotic plaques in SLE-APS and SLE 
aPL-positive patients, while in SLE aPL negative patients and in non SLE patients other 
Ags are involved in sustaining plaque inflammation. With the experimental procedure used 
in this study, the proportion of β2GPI-specific CD4+ T cell clones generated from 
atherosclerotic plaques of atherothrombotic SLE-APS patients is remarkably higher than 
the frequency of β2GPI-specific T cells found in their peripheral blood. 
In order to investigate plaque instability, we investigated fresh T cells coming from the 
atherosclerotic plaques of SLE-APS patients and we found that plaque-derived CD4+ T 
cells specific produce IFN-γ and IL-17 in response to both β2GPI and to mitogen 
stimulation. Studying  at clonal level the β2GPI-specific T cells found in the inflammatory 
atherosclerotic infiltrates of SLE-APS we found that 42% were polarized T helper 1 cells, 
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38% were Th17/Th1 cells, 15% were polarized Th17 cells, 5% were Th0 cells, and none of 
T cells were polarized Th2 cells. The lack of Th2 cells is an important risk factor in the 
genesis of atherosclerosis. T cells indeed play an important role in the genesis of 
atherosclerosis that has been defined a Th1-driven immunopathology [212, 213] and we 
have demonstrated that Th1 cells, producing high levels of IFN-γ, are crucial for the 
development of the disease [89, 191, 206]. Given that atherosclerosis can occur and 
progress even in IFN-γ- or IFN-γR–deficient mice, although with a lower lesion burden 
[214], other Th cells and factors are presumably involved in the genesis of the atheroma. A 
third subset of effector Th cells, namely Th17, has been discovered [215]. Th17 cells are 
potent inducers of tissue inflammation and have been associated with the pathogenesis of 
many experimental autoimmune diseases and human inflammatory conditions [216, 217]. 
In the lymphocytic infiltrates of SLE-APS atherosclerotic plaques, we have found the 
presence of in vivo-activated plaque- infiltrating T cells able to produce IL-17 and IL-21 in 
response to β2GPI. Among the clonal progeny of T cells infiltrating the lesions, we 
demonstrated the presence of β2GPI -specific T cells able to secrete IL-17. A significant 
number (27%) of IL-17–producing T cells are also IFN-γ producers. This finding is in 
agreement with a previous report that demonstrated the concomitant production of IL-17 
and IFN-γ by human coronary artery-infiltrating T cells in non SLE patients [138, 218, 
219]. Plaque rupture and thrombosis are notable complications of atherosclerosis [206, 
219]. The methodology used to obtain the plaque derived T cells encompasses a clonal 
expansion step, followed by limiting dilution to obtain single clones. 
The β2GPI-reactive CD4+ T cell clone found in atherosclerotic plaques were unique, based 
on the T-cell receptor-Vβ results obtained in the study. The β2GPI -specific T-cell clones 
revealed their ability not only to induce macrophage production of TF upon antigen 
stimulation but also were able to promote PCA. 
Th17 cells were shown to play a key role in experimental mouse models of atherosclerosis; 
IL-17 is proatherogenic in experimental model of accelerated atherosclerosis in the 
presence of high fat diet (HFD) [220]. In fact, in IL-17−/− mice fed with HFD, the aortic 
lesion size and lipid composition as well as macrophage accumulation in the plaques were 
significantly diminished, and the progression of the process was remarkably reduced 
compared with WT mice. Furthermore IL-21 was produced by almost all Th1 and 
Th17/Th1 cells specific for β2GPI. IL-21 is actually up-regulated in patients with 
peripheral artery diseases [221]. Expression of IL-17 in human atherosclerotic lesions is 
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associated with increased inflammation and plaque vulnerability and increased Th17 cells 
[222]. An increased incidence of atherosclerosis associated with peripheral blood Th17 
responses has been demonstrated in patients with SLE [223]. 
We have demonstrated that β2GPI was able to activate Th17 and Th1 responses in 
atherosclerotic lesions of SLE-APS patients. The relevance of Th17/Th1 cells in non SLE 
atherosclerosis patients have been demonstrated in other studies [224, 225], suggesting that 
Th1 and Th17 cells might plastically shift one into the other in different phases of the 
disease. It has been shown that Th17 cells might shift towards Th1 but not to Th2 via IL-12 
receptor signalling [226]. 
Overall, our findings support the concept that a crucial component of atherosclerosis in 
SLE-APS is represented by T-cell–mediated immunity and that chronic Th response 
against β2GPI plays important role in the genesis of atheroma in SLE-APS patients [159]. 
Among β2GPI-specific IL-17–producing Th cells, the majority were polarized Th17 cells, 
whereas others were able to produce both IFN-γ and IL-17. Thus, it is possible to speculate 
that Th17 and Th1 cells co-migrate to the inflamed tissue and cooperate in the ongoing 
inflammatory process within the atherosclerotic lesion [87, 206, 216, 227]. 
In addition, upon appropriate Ag stimulation, the majority of atherosclerotic plaque-
derived β2GPI- specific clones induced both perforin-mediated cytolysis and Fas/FasL-
mediated apoptosis in target cells and were able to drive the up-regulation of TF 
production by monocytes within atherosclerotic plaques, thus further contributing to the 
thrombogenicity of lesions [138, 157, 219]. Our results demonstrate that β2GPI is a major 
factor able to drive Th17 and Th1 inflammatory process in SLE- APS atherosclerosis and 
suggest that Th17/Th1 cell pathway and β2GPI may represent important targets for the 
prevention and treatment of the disease. 
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